Traditional chinese medicine composition for treating cold in children

LAP938AUndetermined Publication Date: 2026-04-10HEBEI YILING MEDICINB RESEARCH INSTITUTE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP938
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-04-08
Filing Date
2022-06-01
Publication Date
2026-04-10

AI Technical Summary

Technical Problem

There is a lack of safe and effective drugs in the treatment of children's colds. Existing Western drugs have problems with adverse reactions and viral resistance. The market is in urgent need of a traditional Chinese medicine composition suitable for children.

Method used

Developed a traditional Chinese medicine composition based on Lianhua Qingwen, adjusted the formula and dosage, removed Mianma Guanzhong and Houttuynia cordata, added Shan Yinhua, replaced menthol with mint, and combined Yinqiao Powder The ingredients form a combination of forsythia, mountain honeysuckle, ephedra, gypsum, isatis root, patchouli, rhubarb, rhodiola, and licorice. It is suitable for children's physiological characteristics and has the effects of cooling the skin, relieving the lungs and releasing heat.

Benefits of technology

The composition has shown significant antipyretic effect in clinical trials, is safe and reliable, has no adverse reactions, is as effective as Lianhua Qingwen, is suitable for children's taste, has antiviral properties, and is effective against multiple strains of influenza viruses and respiratory syncytial viruses. Antiviral effects in vitro and in vivo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention seeks to protect a traditional Chinese medicine composition for treating cold of children. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 250-400 parts of Fructus Forsythiae, 250-400 parts of Lonicerae Flos,50-150 parts of ephedra, 50-150 parts of bitter apricot seed,250-400 parts of gypsum,250-400 parts of Radix Isatidis, 50-150 parts of Herba Pogostemonis, 30-90 parts of Radix et Rhizoma Rhei, 10-50 parts of Herba Rhodiolae, 120-280 parts of Menthae Haplocalycis Herba, and 50-150 parts of Radix Glycyruhizae. The experimental results show that the medicament of the present invention has a remarkable effect on common cold and influenza.
Need to check novelty before this filing date? Find Prior Art

Description

Traditional Chinese medicine composition for treating children's colds Technical Field

[0001] The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating children's colds. Background Art

[0002] Influenza (hereafter referred to as flu) is a major public health problem facing humanity. Caused by influenza viruses, there have been six documented influenza pandemics since 1889. In the past decade, outbreaks have occurred, including influenza A (H1N1), influenza B, and avian influenza H7N9. Influenza viruses are highly susceptible to recombination and mutation, spreading rapidly and causing seasonal epidemics each year. Some cases can develop severe influenza due to complications such as pneumonia. A small number of severe cases progress rapidly and can lead to death from acute respiratory distress syndrome (ARDS) and / or multiple organ failure. Children are susceptible to and at high risk of influenza, and outbreaks can occur in schools and childcare facilities where children gather.

[0003] Currently, there are 247 million children aged 0 to 15 years old, accounting for 17.80% of the total population. Respiratory diseases are the most common childhood illness. A survey of 3,576 children aged 0 to 14 years old in over 100 cities showed that the top three diseases in terms of prevalence were colds (74.7%), fever (59.8%), and coughs (56.0%). Colds are the most common respiratory disease in children, occurring 6 to 8 times a year. 10% to 15% of children experience up to 12 colds per year, making them the most common respiratory disease. Cold-related pathogens include rhinoviruses, coronaviruses, respiratory syncytial viruses, parainfluenza viruses, adenoviruses, and enteroviruses. These viruses are transmitted through coughs and sneezes via respiratory droplet aerosols, first attaching to M cells in the adenoid lymphoepithelial region and then reaching the back of the nose via cilia in the nasal mucosa, causing edema and congestion of the respiratory mucosa, leading to exudate. The disease often occurs during the transition between seasons, especially in winter and spring. It has an acute onset, with symptoms primarily characterized by fever, nasal congestion, sore throat, cough, sneezing, and runny nose. An estimated 10% to 15% of children require medical attention each year due to influenza infection. During influenza season, over 40% of preschoolers and 30% of school-age children may contract influenza. Children under six months of age are less susceptible to influenza due to passive maternal immunity. However, those aged six months to three years are at high risk for severe influenza and have a higher incidence of complications. Children and adolescents aged five to 20 years are at high risk for influenza. During epidemics, the infection rate in this age group can reach approximately 50%, 1.5-3 times higher than in adults. Infected individuals typically excrete the virus 24-48 hours before the onset of clinical symptoms. Excretion increases significantly 0.5-1.0 days after infection, peaking within 24 hours of onset. Influenza in children presents with sudden onset of fever, which can reach as high as 39-40°C, accompanied by chills, rigors, headache, generalized muscle aches, fatigue, and loss of strength. Cough, sore throat, runny nose, or nasal congestion are common, and nausea, vomiting, and diarrhea may occur in some cases. Gastrointestinal symptoms are more common in children than in adults. Influenza in infants and young children presents with atypical clinical presentations, and influenza is rare in neonates. However, influenza can be complicated by pneumonia. Acute laryngitis, acute otitis media, tracheitis, bronchitis, bronchiolitis, and pneumonia caused by influenza viruses are more common in children than in adults. Symptoms in most uncomplicated children with influenza resolve within 3-7 days, but coughing and recovery of strength often take 1-2 weeks. Adults and older children typically shed the virus for 5 days (3-8 days), although this duration varies depending on the strain. Younger children shed the same amount of virus as adults at onset, but over a longer period. Compared to adults, prolonged shedding (1-3 weeks) is more common in infants and young children. Therefore, children are actually the most important source of influenza infection, and are also the cause of repeated or acute exacerbation of children's illness. Timely treatment of influenza in children is of great significance to protecting children's health and reducing additional medical expenses.

[0004] Western medicine does not have specific antiviral drugs for the common cold. Commonly used medicines for children's colds include antiviral drugs such as neuraminidase inhibitors (oseltamivir, zanamivir) and M2 ion channel blockers (amantadine and rimantadine). However, clinical applications are plagued by many adverse reactions and viral resistance issues. Currently, the market share and market demand for children's medicines continue to rise. In 2019, the sales of traditional Chinese medicines for pediatric use in public medical institutions reached 8.905 billion yuan, an increase of 11.61% year-on-year. However, there are few special dosage forms and specifications for children's medicines, and the variety is scarce. The market urgently needs a safe and effective medicine for children's colds.

[0005] Viral respiratory infections (VRIs) are acute respiratory infections caused by various viruses. They are divided into upper respiratory infections (URIs) and lower respiratory infections (LUIs). The former manifests as acute rhinitis, pharyngitis, and laryngitis, while the latter manifests as acute tracheitis, bronchitis, and pneumonia. These diseases have a high incidence rate and are common in the general population, with children, the elderly, those with malnutrition, and those with chronic illnesses being particularly susceptible. It is noteworthy that VRIs have become prevalent worldwide following the spread of the 2019 novel coronavirus disease (COVID-19).

[0006] Due to their immature immune systems, children may be more susceptible to infectious viruses than adults, with infants and young children being particularly vulnerable to respiratory infections. Among children, respiratory infections still have higher mortality and morbidity rates than any other illness. Currently, viral respiratory infections are a common pediatric condition, ranking first in both outpatient and inpatient visits, posing a serious threat to children's health. Influenza alone causes approximately 870,000 hospitalizations for children under the age of five worldwide each year.

[0007] Furthermore, the incidence of viral lower respiratory tract infections has been increasing in recent years. For example, according to etiological studies, viral pneumonia accounts for approximately 18% of community-acquired pneumonia and 5% of hospital-acquired infections during the same period, attracting increasing attention. Therefore, finding a quick and effective cure for respiratory viral infections is of paramount importance.

[0008] Summary of the Invention

[0009] Children's physiological characteristics are characterized by delicate internal organs and an inadequate physical energy. These "developed but not complete" and "complete but not strong" characteristics of their internal organs contribute to their pathological characteristics of being easily deficient and overactive, and susceptible to both cold and heat. Children's "qi and meridians are not properly regulated, their internal organs are fragile and thin, and their pores are open and loose." They are immature and unaware of their own health, unable to tell when they are experiencing cold or heat, and completely dependent on their families for care. Their "spirits are frivolous, their temperaments are undetermined, and they dress indiscriminately. They may also indulge themselves, indulge in excessive amounts of raw and cold food, or overindulge in both hot and cold foods. These can all lead to dysfunctional pores, weakened defenses, and susceptible to external pathogens, leading to colds. Children's colds are first invaded by wind evil, and the initial site of the evil is the skin and muscles of the body. Heat is a yang evil, and its nature is burning and inflaming. When wind-heat causes disease, the child will have a high fever, a mild aversion to cold, and sweat or little sweat. When heat evil disturbs the clear orifices, the child will have a headache. When wind-heat blocks the throat and damages the body fluids, the child will have a red, swollen, painful throat and dry mouth. Clinically, headache, body pain and other head and face sensations can be seen.

[0010] The lungs govern qi and respiration, dispersing and descending qi. Externally, they connect to the skin and fur, protecting the body from external pathogens. The mouth, nose, and skin are passageways for external pathogens to enter. When the lung meridians function properly to protect, warm, and nourish the body, the six external pathogens are less likely to invade and cause harm. Children's skin is delicate and fragile, with thin defenses, allowing pathogenic qi to easily enter through the surface, leaving the delicate lungs vulnerable. Exogenous wind-heat pathogens are the first to strike the lungs, and since children often have deficient lungs, the common cold in children is primarily a lung disease.

[0011] Children's constitution is characterized by a "pure yang" constitution. They are full of vitality, develop rapidly, and have abundant blood and qi, which fumigates both internally and externally, easily transforming into heat. Exogenous pathogens, such as the six pathogenic factors, can easily transform into fire, manifesting as internal heat. This can also be caused by "heat in the heart and lungs, which is relieved by wind, causing wind pathogenicity to injure the skin and enter the internal organs." The pathogenesis of wind-heat congestion in the lungs caused by the invasion of exogenous pathogens in children stems from the combined effects of wind-heat and the child's pure yang constitution, which accumulates heat and impairs both the lung and the Defence Qi.

[0012] The Yang meridians of the skin are the seat of the lungs. Wei Qi relies on the lung's Qi meridians to disperse and spread, strengthening the muscles and skin to perform its defensive function. If wind-heat attacks the surface, the Yang meridians become blocked, lung Qi stagnates, and the defense mechanism loses its strength. Wind-heat pathogens can enter through the mouth, nose, or skin, preventing lung Qi from spreading. Abnormal airway opening and closing and contraction lead to airway obstruction, preventing turbid Qi from escaping. This prevents the lung Qi from rising and impacting the glottis, causing cough. The nose is a clear orifice, directly connected to the outside world, and is most vulnerable to invasion by external pathogens. Wind-yang rises and attacks the head and face, obstructing the clear orifices and causing nasal obstruction. With the orifices blocked, the struggle between good and evil forces occurs, and expelling the evil leads to frequent sneezing. External pathogens enter with the Qi and invade the nose, preventing the body from collecting fluid and causing runny nose. In addition, the lungs and large intestine are exterior and interior to each other. Lung heat can easily cause dry and hard stools when it presses down the meridians onto the large intestine. Timely clearing of the bowels can help the lung heat to be discharged from the gate of the soul, clearing the bowels and releasing heat to clear the lungs.

[0013] In summary, children's colds are caused by the invasion of wind-heat evil through the skin, mouth and nose. In addition, children's consciousness is not open, and they cannot adjust to cold and heat by themselves, so they are affected by evil and become ill. The lesion site is in the lungs. The wind-heat evil invades the defensive surface and the child's pure yang body is prone to heat, which affects the lung network qi mechanism, causing qi stagnation, lung qi failure, evil heat blocking the lungs, airway stagnation, and both lung and defensive functions being ill.

[0014] The etiology and pathogenesis of children's colds are characterized by external invasion of wind and heat, dysfunction of the defensive surface, evil heat blocking the lungs, and airway obstruction. The inventor proposed the treatment method of "clearing the sense and relieving the exterior, promoting lung function and relieving heat", using pungent and cool herbs to relieve the exterior, clear the external evil, promote lung function and relieve heat, and clear the internal fire, so that the evil qi is removed, the heat disappears, the lungs are restored to function, the airway is unobstructed, and the symptoms of lung defense are eliminated.

[0015] Adhering to the principle of "clear and dynamic internal organs, responding to the treatment as needed," children's physiological and pathological characteristics include delicate internal organs, immature physical and mental energy, prone to illness and rapid transmission, but also vibrant vitality, rapid development, clear and dynamic internal organs, and easy recovery. Therefore, medication for children requires light and flexible use, avoiding heavy and harsh doses. Pediatric colds are often caused by external pathogens of wind and heat invading the lungs, resulting in a short course and mild symptoms. Therefore, treatment should be stopped as soon as the effect is achieved. "Balanced conditioning is the best approach, and tonics and purgatives should not be excessive."

[0016] Lianhua Qinggan, a pediatric formula, is based on Lianhua Qingwen's experience treating colds and influenza in children. Because the disease is located in the lung defense system, and based on the principle of "overcoming what is above," the formula uses light, mild, cooling, and penetrating herbs to achieve the effect of clearing away heat and dispersing it, helping to dissipate pathogenic heat from the surface. This also reflects the lung's position as the highest and most pure of organs. Yinqiao Powder uses honeysuckle and forsythia to dispel wind-heat and clear heat and detoxify, while peppermint dispels wind-heat and soothes the throat. The formula of Ma Xing Shi Gan Tang in Treatise on Febrile Diseases by Zhang Zhongjing of the Han Dynasty is based on its efficacy in relieving evil heat in the lungs. The original formula of Ma Xing Shi Gan Tang is 4 liang of ephedra and half a jin of gypsum, with a ratio of 1:2. In Lianhua Qinggan for children, honey ephedra is used to focus on clearing the lungs and relieving cough, supplemented by sweating and relieving exterior symptoms. Therefore, the ratio of ephedra to gypsum is 1:3 to prevent excessive relief of exterior symptoms. This follows Liu Wansu's treatment principle for children's colds: "It is advisable to prevent minor problems from developing gradually, practice the method of patrolling and guarding, and use nourishing medicine to preserve its true nature."

[0017] This disease is characterized by external invasion of wind-heat, dysfunction of the defensive surface, obstruction of pathogenic heat in the lungs, and stagnation of the airways. Treatment should address both the exterior and interior lung defenses and coordinate the smooth flow of lung qi. Given that this child's external treatments haven't resolved the symptoms while internal treatments are stagnant and fumigating, creating a conflict between the exterior and interior, a pungent and cool herb should be administered to dispel the external pathogens. This will clear the exterior pathogens and allow the internal heat to escape, while simultaneously clearing the internal heat and cooling the heat. Honeysuckle and Forsythia suspensa are excellent at dispersing lung meridian heat pathogens and expelling them. Gypsum is used for its cooling and dispersing properties, expelling the exterior, relieving muscles, and reducing fever. Peppermint dispels wind-heat and clears the throat. Isatis root clears heat and detoxifies, relieving sore throats and reducing swelling. Children's colds spread rapidly, so active intervention is warranted. Pungent and cool herbs expel the wind-heat pathogens outward, while internal heat is cleared and resolved internally. This expelling and cooling effect addresses both the external pathogens and the internal heat. At the same time, based on the relationship between the lungs and the large intestine, purgation is also used while relieving the exterior, aiming to clear the bowels and clear the lungs, and to facilitate the unobstructed flow of bowel qi, which is conducive to the discharge of lung heat with the stool. It is combined with Rhodiola rosea to clear the lungs, remove blood stasis, regulate immunity, and Patchouli to aromatically remove dampness.

[0018] The pharmaceutical composition of the present invention is derived from Lianhua Qingwen, which is composed of 13 medicinal herbs including forsythia, honeysuckle, roasted ephedra, stir-fried bitter almonds, gypsum, isatis root, rhubarb, smilax glabra, houttuynia cordata, patchouli, rhubarb, rhodiola rosea, menthol and licorice. The Lianhua Qinggan prescription for children is based on Lianhua Qingwen, and includes 11 herbs including forsythia, honeysuckle, mint, honeyed ephedra, gypsum, stir-fried bitter almonds, isatis root, patchouli, rhodiola rosea, rhubarb and licorice. Rhubarb and smilax glabra and houttuynia cordata are removed, honeysuckle is replaced by honeysuckle, and menthol is replaced by mint.

[0019] Guanzhong was first mentioned in Shennong's Herbal Classic as a lower-grade herb. It is bitter, slightly cold, and slightly toxic. It enters the liver and stomach meridians, and has the effects of clearing heat and detoxifying, cooling blood, and stopping bleeding. Guanzhong's primary efficacy and clinical research for respiratory diseases focuses on its anti-influenza and antibacterial properties. Children often suffer from liver and kidney dysfunction or weak spleen and stomach, and are prone to vomiting when taking this herb. Taking these factors into consideration, the herb was removed from the prescription.

[0020] Houttuynia cordata is an essential herb for treating phlegm-heat congestion in the lungs and lung abscesses with vomiting of pus and blood. However, in children with colds, the lung defense system is affected and the lesions have not yet reached the stage of phlegm-heat congestion in the lungs and cough with thick sputum. Furthermore, Houttuynia cordata has a fishy smell that is difficult to correct, leading to poor medication compliance. Considering the immature yin and yang constitutions of children and their delicate spleen and stomach, removing the herb Mian Ma Guan Zhong and Houttuynia cordata slows down the heat-clearing and detoxifying effects and prevents damage to the spleen and stomach.

[0021] Honeysuckle and Lonicera japonica are included in the 2020 edition of the Chinese Pharmacopoeia. The two medicinal materials have the same nature and flavor as the meridians (sweet and cold; enter the lung, heart, and stomach meridians), functions and indications (clearing heat and detoxifying, dispersing wind-heat. Used for carbuncle, furuncle, throat paralysis, erysipelas, dysentery due to heat toxins, wind-heat cold, and fever caused by febrile diseases). The usage and dosage (6-15g) are exactly the same, but Honeysuckle is Lonicera japonica. Experiments have shown that Lonicera japonica has a certain effect on the common cold caused by influenza virus. The flavonoids extracted and isolated from Lonicera japonica have different degrees of inhibitory effects on different types of bacteria, and have antibacterial effects on Staphylococcus aureus, Pneumococcus, Corynebacterium diphtheriae, Pseudomonas aeruginosa, etc., and also have strong antibacterial effects on common pathogens and conditional pathogens that cause respiratory tract infections. Considering the antibacterial effects comprehensively, we replaced Lonicera japonica with Honeysuckle in order to achieve a better antibacterial effect.

[0022] Menthol can cause adverse reactions in the digestive system, mainly manifested as a cold and uncomfortable feeling in the stomach. Considering the gastrointestinal dysfunction of children, menthol is adjusted to mint medicinal material and mint oil is extracted for use as medicine.

[0023] In this prescription, the main herbs are Forsythia suspensa and Honeysuckle. Forsythia suspensa is slightly cold in nature, bitter in flavor, and enters the Lung and Heart meridians. It clears heat and detoxifies, dispersing wind-heat. It soothes the skin externally and clears stagnant heat internally. This herb leverages its ascending, dispersing, and purifying properties to reach the surface of the body. Combined with Ephedra, which dissipates lung heat, it dissipates wind-heat pathogenic qi in the lungs, embodying the principle of "releasing stagnant fire." Furthermore, Gypsum and Isatis root aid in clearing heat and detoxifying, targeting exogenous pathogenic qi that enters the interior and accumulates heat. Their pungent, cooling, and clearing properties make them the main herbs. Honeysuckle is sweet and cold in nature, and enters the Lung, Heart, and Stomach meridians. It dissipates wind-heat, clears heat and detoxifies, and is used for wind-heat colds and fevers caused by febrile diseases. This product is sweet and cold and good at dispersing heat evil in the lung meridian, and penetrating heat to the surface. When used with Forsythia suspensa, it helps to clear away the stagnant heat in the lungs. Forsythia suspensa and its flowers must be used together. Both have a fragrant smell. Forsythia suspensa has a strong ability to clear away internal heat and detoxify, while Honeysuckle tends to disperse superficial heat, and its sweet and cold nature does not hurt the spleen and stomach. It can lightly penetrate the surface and evacuate wind-heat, and while dispersing the superficial evil of Wei Qi, it also takes into account the characteristics of exogenous wind-heat evil qi accumulating and turning into heat.

[0024] The assistant medicines are mint, honey ephedra, and gypsum.

[0025] The adjuvant is stir-fried bitter almonds, which are bitter and pungent in flavor and warm in nature, entering the lung and large intestine meridians. Their bitter, purging, and descending properties are known to moisten the lungs and relieve coughs, making them a key remedy for cough and asthma. Almonds and ephedra, when combined, can both dissipate and descend, lowering qi and moistening dryness, restoring their function of calming and descending. Together, they can calm coughs and alleviate them. Their combined dispersing and dispersing properties dispel pathogenic factors and relieve coughs, improving the cough and dyspnea associated with childhood colds.

[0026] Isatis root: Bitter in taste, cold in nature, enters the Heart and Stomach meridians. It clears heat and detoxifies, cools the blood, and relieves sore throats. It is commonly used to treat fever and sore throats caused by external pathogens. It helps clear heat and detoxify, cool the blood, and relieve sore throats in children with colds, which can easily lead to heat accumulation and sore throats.

[0027] Patchouli: Pungent and slightly warm, it enters the spleen, stomach, and lung meridians. Its aromatic properties dissipate dampness, invigorate the spleen and stimulate the appetite, and support stomach qi. Its pungent, dispersing properties are not harsh, and its slightly warming properties dissipate dampness without causing heat. It effectively dissipates dampness and turbidity, invigorates the spleen and stimulates the appetite, and soothes vomiting. Children's stomachs are naturally weak and susceptible to external pathogens, leading to poor appetite and dampness retention. Therefore, patchouli is combined with its aromatic properties to dissipate dampness, stimulate the appetite, and strengthen the spleen, achieving the effect of "invigorating the spleen and stomach, eliminating the evil qi and leading to recovery."

[0028] Rhodiola rosea: Sweet and bitter in flavor, neutral in nature, it enters the lung, spleen, and heart meridians. It has the effects of clearing the lungs, removing blood stasis, and regulating immunity. This prescription uses Rhodiola rosea to boost immunity because children have immature yin and yang bodies, their internal organs are not fully developed, and their resistance is weak. It is also combined with gypsum to clear the lungs and remove blood stasis.

[0029] Rhubarb: Bitter in flavor and cold in nature, it enters the spleen, stomach, large intestine, liver, and pericardium meridians. It clears the bowels and clears the lungs, purging the lungs. Because the lungs and large intestine are exterior and interior to each other, using rhubarb to clear the bowels and lungs allows qi to flow downward, clearing lung heat. Considering that children may not tolerate purgatives, the dosage in this prescription is small, stopping when the symptoms are relieved.

[0030] Drug:

[0031] Licorice: Sweet and neutral in nature, it enters the Heart, Lung, and Spleen and Stomach meridians. It tonifies the spleen and replenishes Qi, moistens the lungs and relieves coughs, and harmonizes various herbs. This sweet and neutral herb, combined with the virtues of earth, enters the spleen and stomach, tonifying Qi, strengthening the spleen, and harmonizing the middle. It also works with bitter almonds to moisten the lungs and relieve coughs, harmonizing various herbs. Therefore, it serves as the guiding herb in this formula.

[0032] In summary, the pharmaceutical composition of the present invention is a prescription formed based on the pathogenesis characteristics of children's colds and the physiological characteristics of the delicate internal organs of children. This prescription is a collection of classic prescriptions, combining the external elimination of pathogenic factors and the clearing of internal heat, while not forgetting to protect the vital energy, strengthen the spleen and stimulate the appetite, and embodying the therapeutic principle of treating both the lung and the outside, eliminating both the exterior and the interior, and strengthening the body's resistance and eliminating pathogenic factors. The prescription is derived from classics and practiced in clinical practice. It is modified in combination with the physiological characteristics of children's diseases and confirmed by experimental studies. The theory of network disease - etiology and pathogenesis - treatment principles and methods - prescription and medication are consistent in principle, method, prescription, and medicine, with a high degree of fit and a reasonable prescription. Corydalis cyrtomii and Houttuynia cordata have been removed, and honeysuckle is replaced by honeysuckle, and mint is replaced by menthol. While reducing the taste of the medicine, it is more suitable for children to take, and its efficacy is comparable to that of Lianhua Qingwen, providing a better choice for the currently most lacking professional children's medicine.

[0033] In view of the above technical problems existing in existing viral respiratory infections, especially children's colds, the present invention provides a traditional Chinese medicine composition with the efficacy of treating children's colds and its application.

[0034] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:

[0035] A traditional Chinese medicine composition for treating children's colds. The composition is composed of the following raw materials in parts by weight: 250-400 parts of forsythia, 250-400 parts of honeysuckle, 50-150 parts of ephedra, 50-150 parts of bitter almonds, 250-400 parts of gypsum, 250-400 parts of isatis root, 50-150 parts of patchouli, 30-90 parts of rhubarb, 10-50 parts of rhodiola, 120-280 parts of mint, and 50-150 parts of liquorice.

[0036] The raw materials of the traditional Chinese medicine composition are preferably: 250 parts of forsythia, 400 parts of honeysuckle, 50 parts of ephedra, 150 parts of bitter almond, 250 parts of gypsum, 400 parts of isatis root, 50 parts of patchouli, 90 parts of rhubarb, 10 parts of rhodiola, 280 parts of mint and 50 parts of liquorice.

[0037] The raw materials of the traditional Chinese medicine composition are preferably: 400 parts of forsythia, 250 parts of honeysuckle, 150 parts of ephedra, 50 parts of bitter almond, 400 parts of gypsum, 250 parts of isatis root, 150 parts of patchouli, 30 parts of rhubarb, 50 parts of rhodiola, 120 parts of mint and 150 parts of liquorice.

[0038] The raw materials of the traditional Chinese medicine composition are preferably: 328 parts of forsythia, 328 parts of honeysuckle, 98 parts of ephedra, 98 parts of bitter almond, 328 parts of gypsum, 328 parts of isatis root, 98 parts of patchouli, 66 parts of rhubarb, 33 parts of rhodiola, 197 parts of mint and 98 parts of liquorice.

[0039] The raw materials of the traditional Chinese medicine composition are preferably: 280 parts of forsythia, 360 parts of honeysuckle, 60 parts of ephedra, 120 parts of bitter almond, 280 parts of gypsum, 360 parts of isatis root, 60 parts of patchouli, 60 parts of rhubarb, 20 parts of rhodiola, 250 parts of mint and 60 parts of liquorice.

[0040] The ephedra described in the traditional Chinese medicine composition of the present invention is honey ephedra, and the bitter almonds described are fried bitter almonds.

[0041] Compared with the prior art, the Chinese medicine composition with the efficacy of treating children's colds provided by the present invention is a Chinese medicine composition suitable for children's colds obtained through a lot of innovative work by the inventors on the basis of the prior art. Specifically, the inventors adjusted the formula and dosage of Lianhua Qingwen, improved the process and corrected the taste in combination with the special physiological stages and physiological and pathological characteristics of children, and invented the Chinese medicine composition of the present invention through multi-index evaluation of efficacy. Among the 11 medicines, the monarch, minister, assistant and envoy complement each other, that is, the Chinese medicine composition for treating children's colds composed of specific medicinal flavors and specific dosage ratios. Compared with Lianhua Qingwen, the Chinese medicine composition of the present invention is as effective as Lianhua Qingwen in treating children's colds with a reduced medicinal flavor, and the taste of the product is improved, making it more suitable for children's medication. Clinical trials have confirmed that the total effective results of the clinical efficacy of the drug prepared by the Chinese medicine composition provided by the present invention for treating children's influenza are much higher than those of the Western medicine control group, oseltamivir, and have better antipyretic efficacy than the Western medicine control group, are safe and reliable, and have no adverse reactions and side effects.

[0042] Children's cold belongs to the category of new diseases entering the network. The present invention is based on the spatial concept of network disease theory and the rules of diagnosis and treatment of lung network lesions. In combination with the fact that children have thin internal organs, loose barriers, and easily open pores, they are more susceptible to external pathogens and become ill than adults. It proposes that "wind-heat invasion, dysfunction of the Wei surface, evil heat blocking the lungs, and airway obstruction" are the main causes and pathogenesis of the disease, establishes the treatment method of "clearing the senses and relieving the exterior, promoting lung function and relieving heat", follows the physiological characteristics of children's "clear and lively internal organs, and responding to the stimulation", uses medicine lightly and flexibly, and stops when the disease is cured; at the same time, it takes into account the coordination of the Wei and lungs inside and outside, actively intervenes, and prevents transmission. The traditional Chinese medicine composition provided by the present invention has the effect of treating children's colds. The whole formula coordinates the exogenous pathogens with the internal clearing of lung heat, and combines clearing and strengthening the body. It fully considers the physiological characteristics of children's diseases, eliminates pathogens without harming the body, and conforms to the treatment strategy of "active intervention" in the treatment of lung network syndrome. The formula is derived from classics and practiced in clinical practice, and embodies the research idea of ​​etiology and pathogenesis - treatment principles and methods - prescription and medication under the guidance of network disease theory, and integrates theory, method, prescription and medicine.

[0043] The present invention also provides use of the traditional Chinese medicine composition in treating children's colds, wherein the cold is preferably influenza or common cold.

[0044] Pharmacological and clinical trials have confirmed that the clinical efficacy of the drug provided by the present invention in treating influenza in children is much higher than that of the Western medicine control group, oseltamivir, and has a better antipyretic effect than the Western medicine control group, and does not cause any nausea, diarrhea, vomiting, abdominal pain, abdominal distension, dry mouth, as well as gastrointestinal adverse reactions such as rash, itching, dizziness, and other side effects; compared with Lianhua Qingwen, although some medicinal materials have been removed and replaced, the effects are equivalent, which proves that the Chinese medicine composition of the present invention is very safe for children.

[0045] The invention also provides application of the traditional Chinese medicine composition in antipyretic medicine.

[0046] The present invention also provides application of the traditional Chinese medicine composition in the preparation of anti-inflammatory and analgesic drugs.

[0047] The invention also provides application of the traditional Chinese medicine composition in preparing medicines for treating cough, nasal congestion and sore throat.

[0048] The present invention also provides the use of the above-mentioned traditional Chinese medicine composition with the efficacy of treating children's colds in the preparation of anti-respiratory tract infection virus drugs.

[0049] The traditional Chinese medicine composition provided by the present invention, which is effective in treating children's colds, has in vitro antiviral effects against multiple strains of influenza A virus, influenza B virus, respiratory syncytial virus, and coronavirus, acting at the early stages of viral replication. Simultaneously, the composition has significant in vivo efficacy against influenza A virus and respiratory syncytial virus. Common pathogens of viral respiratory infections include rhinoviruses, influenza viruses, parainfluenza viruses, respiratory syncytial virus, and coronaviruses. Therefore, the traditional Chinese medicine composition provided by the present invention can be used in the preparation of antiviral drugs for respiratory infections.

[0050] Furthermore, the above-mentioned anti-respiratory tract infection viral drug is a drug for treating viral upper respiratory tract infection and / or viral lower respiratory tract infection.

[0051] Furthermore, the above-mentioned anti-respiratory tract infection virus drug is a drug for treating acute rhinitis, acute pharyngitis, tonsillitis, and laryngitis.

[0052] Furthermore, the above-mentioned anti-respiratory virus drug is a drug for treating acute tracheobronchitis or pneumonia.

[0053] The active ingredients of the Chinese medicine composition of the present invention are prepared by the following steps:

[0054] (1) Weighing patchouli and mint according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil and setting aside; filtering the aqueous solution after distillation to obtain a volatile oil extract, and setting aside;

[0055] (2) weighing the medicinal ingredients except those in step (1) according to the prescribed amount, adding water and boiling, combining the filtrate with the volatile oil extract in step (1), concentrating, filtering, and setting aside;

[0056] The volatile oil obtained in step (1) and the extract obtained in step (2) together constitute the active ingredient of the Chinese medicine composition of the present invention.

[0057] The active ingredients of the preferred Chinese medicine composition of the present invention are prepared by the following steps:

[0058] (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water. Extract the volatile oil by steam distillation for 8 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0059] (2) Weigh the amount of the medicinal ingredients except those in step (1) according to the prescription, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, and set aside;

[0060] The volatile oil obtained in step (1) and the extract obtained in step (2) together constitute the active ingredient of the Chinese medicine composition of the present invention.

[0061] The invention also provides the dosage form of the traditional Chinese medicine composition, which is capsule, tablet, granule, injection, pill, powder and oral liquid.

[0062] In order to realize the above dosage forms, pharmaceutically acceptable excipients such as fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, matrix, etc. need to be added when preparing these dosage forms. Fillers include: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; disintegrants include: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, etc.; lubricants include: magnesium stearate, sodium lauryl sulfate, talc, silicon dioxide, etc.; suspending agents include: polyvinyl pyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, etc.; binders include: starch slurry, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, etc.; sweeteners include: sodium saccharin, aspartame, sucrose, cyclamate, glycyrrhetinic acid, etc.; flavorings include: sweeteners and various flavors; preservatives include: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroethidine acetate, eucalyptus oil, etc.; matrices include: PEG6000, PEG4000, insect wax, etc.

[0063] The granules of the Chinese medicine composition of the present invention are prepared by the following steps:

[0064] (1) Weighing patchouli and mint according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil and setting aside; filtering the aqueous solution after distillation to obtain a volatile oil extract, and setting aside;

[0065] (2) Weighing the medicinal ingredients except those in step (1) according to the prescribed amount, adding water and boiling, combining the filtrate with the volatile oil extract obtained in step (1), concentrating, filtering, and drying to obtain a dry paste powder for later use;

[0066] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0067] (4) Add appropriate amount of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), and granulate them to prepare granules according to conventional methods.

[0068] Preferably, the granules of the Chinese medicine composition of the present invention are prepared by the following steps:

[0069] (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water. Extract the volatile oil by steam distillation for 8 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0070] (2) Weigh the amount of the medicinal ingredients except for the medicinal ingredients in step (1) according to the prescription, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, spray dry to obtain a dry paste powder, and set aside;

[0071] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0072] (4) Add appropriate amount of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), adopt dry granulation method, and prepare granules according to conventional methods.

[0073] The Chinese medicine composition tablets of the present invention are prepared by the following steps:

[0074] (1) Weighing patchouli and mint according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil and setting aside; filtering the aqueous solution after distillation to obtain a volatile oil extract, and setting aside;

[0075] (2) Weighing the medicinal ingredients except those in step (1) according to the prescribed amount, adding water and boiling, combining the filtrate with the volatile oil extract obtained in step (1), concentrating, filtering, and drying to obtain a dry paste powder for later use;

[0076] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0077] (4) Add appropriate amounts of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), and prepare tablets according to conventional methods.

[0078] The Chinese medicine composition capsule of the present invention is prepared by the following steps:

[0079] (1) Weighing patchouli and mint according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil and setting aside; filtering the aqueous solution after distillation to obtain a volatile oil extract, and setting aside;

[0080] (2) Weighing the medicinal ingredients except those in step (1) according to the prescribed amount, adding water and boiling, combining the filtrate with the volatile oil extract obtained in step (1), concentrating, filtering, and drying to obtain a dry paste powder for later use;

[0081] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0082] (4) Add appropriate amounts of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3) and prepare capsules according to conventional methods.

[0083] The Chinese medicine composition of the present invention is a Chinese medicine composition suitable for children's colds obtained through a lot of innovative work by the inventors on the basis of the existing technology. Specifically, the inventors adjusted the formula and dosage of Lianhua Qingwen, improved the process and corrected the taste in combination with the special physiological stages and physiological and pathological characteristics of children, and invented the Chinese medicine composition of the present invention through multi-index evaluation of efficacy, that is, a Chinese medicine composition for treating children's colds with a specific medicinal flavor composition and a specific dosage ratio. Compared with Lianhua Qingwen, the Chinese medicine composition of the present invention has an effect on treating children's colds that is equivalent to Lianhua Qingwen with a reduced medicinal flavor, and the taste of the product is improved, making it more suitable for children's medication. Clinical trials have confirmed that the total effective results of the clinical efficacy of the drug of the present invention in treating influenza in children are much higher than those of the Western medicine control group, oseltamivir. The drug of the present invention has a better antipyretic effect than the Western medicine control group, and does not cause any nausea, diarrhea, vomiting, abdominal pain, abdominal distension, dry mouth, as well as gastrointestinal adverse reactions such as rash, itching, dizziness, and other side effects, proving that the Chinese medicine composition of the present invention is very safe as a medicine for children. BRIEF DESCRIPTION OF THE DRAWINGS

[0084] FIG1 shows the inhibition rate of LHQG on different cells in Experimental Example 5 of the present invention (MTT method);

[0085] FIG2 shows the effect of LHQG on the expression of influenza virus NP protein in Experimental Example 5 of the present invention;

[0086] FIG3 shows the effect of LHQG on lung tissue pathology in the in vivo pharmacodynamic study against influenza A virus in Test Example 7 of the present invention (24 h after infection);

[0087] FIG4 shows the results of the effect of LHQG on lung tissue pathology in the in vivo pharmacodynamic study against influenza A virus in Test Example 7 of the present invention (2 hours after the last administration);

[0088] FIG5 is a graph showing the effect of LHQG on CD4 in lung tissue in the in vivo pharmacodynamic study of anti-influenza A virus in Experimental Example 7 of the present invention. + 、CD8 + Effect results of cell fluorescence intensity value (24h after infection);

[0089] FIG6 is a graph showing the effect of LHQG on CD4 in lung tissue in the in vivo pharmacodynamic study of anti-influenza A virus in Experimental Example 7 of the present invention. + 、CD8 + Effect results of cell fluorescence intensity values ​​(2 h after the last administration);

[0090] FIG7 shows the results of the effect of LHQG on lung tissue pathology in the in vivo pharmacodynamic study against respiratory syncytial virus in Test Example 7 of the present invention (24 h after infection);

[0091] FIG8 shows the results of the effect of LHQG on lung tissue pathology in the in vivo pharmacodynamic study against respiratory syncytial virus in Test Example 7 of the present invention (2 hours after the last administration);

[0092] Figure 9 shows the effect of LHQG on CD4 in lung tissue in the in vivo pharmacodynamic study of anti-respiratory syncytial virus in Experimental Example 7 of the present invention. + 、CD8 + Effect results of cell fluorescence intensity value (24h after infection);

[0093] FIG10 is a graph showing the effect of LHQG on CD4 in lung tissue in the in vivo pharmacodynamic study of anti-respiratory syncytial virus in Experimental Example 7 of the present invention. + 、CD8 + Results of the effects of cell fluorescence intensity values ​​(2 h after the last administration). DETAILED DESCRIPTION

[0094] The technical solutions of the present invention are described in detail below in conjunction with the embodiments, but the protection scope of the present invention includes but is not limited to them.

[0095] Example 1: Preparation of the pharmaceutical granules of the present invention

[0096] A traditional Chinese medicine composition with the effect of treating children's colds, prescription: 328g of forsythia, 328g of honeysuckle, 98g of honey ephedra, 98g of stir-fried bitter almonds, 328g of gypsum, 328g of isatis root, 98g of patchouli, 66g of rhubarb, 33g of rhodiola rosea, 197g of mint, and 98g of licorice.

[0097] Preparation method:

[0098] (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water. Extract the volatile oil by steam distillation for 8 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0099] (2) Weigh the amount of the medicinal ingredients except for the medicinal ingredients in step (1) according to the prescription, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, spray dry to obtain a dry paste powder, and set aside;

[0100] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0101] (4) Add sucralose and maltodextrin to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), mix well, and dry granulate to obtain granules for later use.

[0102] Example 2: Preparation of the pharmaceutical capsule of the present invention

[0103] A traditional Chinese medicine composition with the effect of treating children's colds, prescription: 350g of Forsythia suspensa, 350g of Honeysuckle, 100g of Honeyed Ephedra, 100g of Fried Bitter Almonds, 350g of Gypsum, 350g of Isatis Root, 100g of Patchouli, 70g of Rhubarb, 35g of Rhodiola rosea, 210g of Mint, and 100g of Licorice.

[0104] Preparation method:

[0105] (1) Weigh patchouli and mint according to the prescribed amount and add 12 times the amount of water. Extract the volatile oil by steam distillation for 6 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0106] (2) Weigh the amount of the medicinal ingredients except those in step (1) according to the prescription, add 12 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, spray dry to obtain a dry paste powder, and set aside;

[0107] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0108] (4) Add dextrin to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), mix them evenly, granulate them, and encapsulate them for later use.

[0109] Example 3: Preparation of the pharmaceutical tablets of the present invention

[0110] A traditional Chinese medicine composition with the effect of treating children's colds, prescription: 250g of Forsythia suspensa, 400g of Honeysuckle, 50g of Ephedra, 150g of Bitter Almond, 250g of Gypsum, 400g of Isatis Root, 50g of Patchouli, 90g of Rhubarb, 10g of Rhodiola rosea, 280g of Mint, and 50g of Licorice.

[0111] Preparation method:

[0112] (1) Weigh patchouli and mint according to the prescribed amount and add 8 times the amount of water. Extract the volatile oil by steam distillation for 12 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0113] (2) Weigh the amount of the medicinal ingredients except those in step (1) according to the prescription, add 8 times the amount of water and boil twice, each time for 1.5 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, and dry under reduced pressure to obtain a dry paste powder for later use;

[0114] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0115] (4) Add starch to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), mix them evenly, granulate them, dry them to obtain granules, press them into tablets, and set them aside.

[0116] Example 4:

[0117] A traditional Chinese medicine composition with the effect of treating children's colds, prescription: 350g of Forsythia suspensa, 350g of Honeysuckle, 100g of Honeyed Ephedra, 100g of Fried Bitter Almonds, 350g of Gypsum, 350g of Isatis Root, 100g of Patchouli, 70g of Rhubarb, 35g of Rhodiola rosea, 210g of Mint, and 100g of Licorice.

[0118] Preparation method:

[0119] (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water. Extract the volatile oil by steam distillation for 8 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0120] (2) Weigh the amount of the medicinal ingredients except for the medicinal ingredients in step (1) according to the prescription, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, spray dry to obtain a dry paste powder, and set aside;

[0121] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0122] (4) The dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3) are made into pills according to conventional methods.

[0123] Example 5

[0124] A traditional Chinese medicine composition with the effect of treating children's colds is composed of the following raw materials in parts by weight, namely, the prescription is: 280g of forsythia, 360g of honeysuckle, 60g of ephedra, 120g of bitter almond, 280g of gypsum, 360g of isatis root, 60g of patchouli, 60g of rhubarb, 20g of rhodiola, 250g of mint and 60g of liquorice.

[0125] The above-mentioned Chinese medicine composition is prepared into tablets, and the preparation method specifically comprises the following steps:

[0126] (1) Weigh patchouli and mint according to the prescribed amount and add 8 times the amount of water. Extract the volatile oil by steam distillation for 12 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0127] (2) Weigh the other medicinal ingredients except the Chinese medicinal ingredient in step (1) according to the prescribed amount, add 8 times the amount of water and boil twice, each time for 1.5 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, and dry under reduced pressure to obtain a dry paste powder for later use;

[0128] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0129] (4) Add starch to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), mix them evenly, granulate them, dry them to obtain granules, press them into tablets, and set them aside.

[0130] Example 6

[0131] A traditional Chinese medicine composition with the effect of treating children's colds is composed of the following raw materials in parts by weight, namely, the prescription is: 400g of Forsythia suspensa, 250g of Honeysuckle, 150g of Ephedra, 50g of Bitter Almond, 400g of Gypsum, 250g of Isatis Root, 150g of Patchouli, 30g of Rhubarb, 50g of Rhodiola rosea, 120g of Mint and 150g of Licorice.

[0132] The above-mentioned Chinese medicine composition is prepared into granules, and the preparation method specifically comprises the following steps:

[0133] (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water. Extract the volatile oil by steam distillation for 8 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0134] (2) Weigh the other medicinal ingredients except the Chinese medicinal ingredient in step (1) according to the prescribed amount, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, spray dry to obtain a dry paste powder, and set aside;

[0135] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0136] (4) Add sucralose and maltodextrin to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), mix well, and dry granulate to obtain granules for later use.

[0137] Comparative Example 1: Substituting wild chrysanthemum for honeysuckle, the other drugs and their dosage ratios remain unchanged

[0138] Prescription: Forsythia suspensa 328g, wild chrysanthemum 328g, honey ephedra 98g, fried bitter almond 98g, gypsum 328g, isatis root 328g, patchouli 98g, rhubarb 66g, rhodiola rosea 33g, mint 197g, licorice 98g.

[0139] Preparation method:

[0140] (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water. Extract the volatile oil by steam distillation for 8 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0141] (2) Weigh the amount of the medicinal ingredients except for the medicinal ingredients in step (1) according to the prescription, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, spray dry to obtain a dry paste powder, and set aside;

[0142] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0143] (4) Add sucralose and maltodextrin to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), mix well, and dry granulate to obtain granules for later use.

[0144] Comparative Example 2: Replace Forsythia suspensa with Viola yedoensis, while other drugs and their dosage ratios remain unchanged

[0145] Prescription: Viola yedoensis 328g, honeysuckle 328g, honey ephedra 98g, stir-fried bitter almond 98g, gypsum 328g, isatis root 328g, patchouli 98g, rhubarb 66g, rhodiola rosea 33g, mint 197g, licorice 98g

[0146] Preparation method:

[0147] (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water. Extract the volatile oil by steam distillation for 8 hours. Collect the volatile oil and set aside. Filter the distilled aqueous solution to obtain the volatile oil extract and set aside.

[0148] (2) Weigh the amount of the medicinal ingredients except for the medicinal ingredients in step (1) according to the prescription, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60°C), filter, spray dry to obtain a dry paste powder, and set aside;

[0149] (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound;

[0150] (4) Add sucralose and maltodextrin to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), mix well, and dry granulate to obtain granules for later use.

[0151] Test Example 1

[0152] In order to illustrate the safety of the Chinese medicine composition of the present invention, a toxicity test was conducted using the granules prepared in Example 1 (hereinafter referred to as the Chinese medicine composition of the present invention (LHQG: Xiaoer Lianhua Qinggan)).

[0153] The toxicity test of the Chinese medicinal composition of the present invention was conducted by repeated oral administration to young SD rats for 6 weeks and a recovery period of 4 weeks.

[0154] The purpose of this study is to evaluate the possible toxic reactions (including developmental toxicity), target organs and recovery of toxic reactions 4 weeks after repeated oral administration of the Chinese medicine composition of the present invention to young SD rats for 6 weeks, and to provide animal test data for clinical research of the test product.

[0155] Two hundred juvenile Sprague-Dawley rats (postnatal day 21, PND21), half male and half female, were randomly divided into eight groups based on sex. Groups 1 to 4 served as toxicology groups, each consisting of 30 rats (half male and half female), including a vehicle control group (sterile water for injection), a low-dose group (6 g crude drug / kg / day), a medium-dose group (12 g crude drug / kg / day), and a high-dose group (24 g crude drug / kg / day). Groups 5 to 8, each consisting of 20 rats (half male and half female), were used for behavioral function and estrous cycle assessments. Doses were administered by gavage starting on postnatal day 21 (PND21) and continued once daily for six weeks until the Sprague-Dawley rats reached adulthood, a total of 42 doses. During the trial, the animals underwent clinical observations, body weight, food intake, physical development, behavioral development, blood cell count, coagulation function, blood biochemistry, urinalysis, and ophthalmological examinations. Male sperm count and motility, sperm morphology, and female estrous cycle were also examined. The day after the final dose, some animals were euthanized, while the remaining animals were allowed a four-week recovery period before being euthanized. Following euthanasia, gross autopsies were performed, major organs were weighed, organ-to-body ratios and organ-to-brain ratios were calculated, and histopathological examinations of over 40 tissues and organs were performed.

[0156] During the trial, no abnormal changes related to the test article were observed in the body weight, food intake, ophthalmological examination, urinalysis, blood cell count, coagulation indexes, and blood biochemical indexes of the animals in each dose group; no obvious abnormal changes related to the test article were observed in the growth and development indicators including growth rate per unit time, physical development indicators (the standard age of vaginal opening, testicular descent and foreskin separation, body length, tail length and tibia length), behavioral development indicators (total distance and number of activities of animals in the spontaneous activity test, spontaneous alternation rate of animals in the Y maze test), and reproduction-related indicators (sperm count and motility of male mice, sperm morphology, and irregular estrous cycle rate of female mice).

[0157] Under the experimental conditions, the Chinese herbal composition of the present invention was repeatedly administered orally to young SD rats at doses of 6, 12, and 24 g of crude drug / kg / day, once daily for 6 consecutive weeks, followed by a 4-week recovery period. No growth and developmental toxicity or systemic toxicity related to the test product was observed at doses of 6, 12, and 24 g of crude drug / kg / day, demonstrating the safety of the Chinese herbal composition of the present invention in young SD rats.

[0158] Test Example 2:

[0159] To illustrate the activity of the Chinese herbal composition of the present invention in treating colds, the granules prepared in Example 1 (hereinafter referred to as the Chinese herbal composition of the present invention) were used to conduct the following efficacy screening test.

[0160] 1 Experimental Purpose

[0161] This experiment used a mouse ammonia spray-induced cough model (antitussive), a mouse tracheal segment phenol red secretion model (expectorant), a rat intraperitoneal injection of lipopolysaccharide (LPS)-induced fever model (antipyretic), and a mouse xylene-induced ear swelling model (anti-inflammatory) to screen the optimal formula of the Chinese medicine composition (LHQG) of the present invention.

[0162] 2 Test methods

[0163] 2.1 Antitussive test

[0164] KM mice, half male and half female, were randomly divided into six groups according to body weight: a model group, a dextromethorphan group, a Lianhua Qingwen group, a Chinese medicine composition of the present invention (LHQG) group, a comparative example 1 (LHQG-A) group, and a comparative example 2 (LHQG-B) group. The proposed clinical dose was 0.4 g of crude drug / kg body weight, and the mouse dose was set at 4.0 g of crude drug / kg, which is 10 times the proposed clinical dose and the clinical equivalent dose. The drug was administered once daily for 3 consecutive days. Coughing was induced approximately 0.5 h after the last dose, and the cough latency and number of coughs within 3 minutes were recorded.

[0165] 2.2 Expectorant test

[0166] KM mice, half male and half female, were randomly divided into 6 groups according to body weight, namely the model group, ambroxol group, Lianhua Qingwen group, the Chinese medicine composition of the present invention (LHQG) group, comparative example 1 (LHQG-A) group, and comparative example 2 (LHQG-B) group. The proposed clinical dose is 0.4g crude drug / kg body weight, and the mouse dose is set at 4.0g crude drug / kg, which is 10 times the proposed clinical dose. This is the clinical equivalent dose. The drug was administered continuously for 3 days, once a day. About 0.5 hours after the last administration, the mice were intraperitoneally injected with 2.5% phenol red solution. 0.5 hours later, the animals were killed by cervical dislocation, and the same section of trachea was cut and placed in a test tube containing 2ml of normal saline. At the same time, 0.1ml of 1mol / l NaOH solution was added. The absorbance value was measured at a wavelength of 546nm to calculate the phenol red concentration.

[0167] 2.3 Antipyretic test

[0168] Male SD rats were randomly divided into 6 groups according to basal body temperature, namely model group, ibuprofen group, Lianhua Qingwen group, Chinese medicine composition of the present invention (LHQG) group, comparative example 1 (LHQG-A) group, comparative example 2 (LHQG-B) group. The proposed clinical dose is 0.4g crude drug / kg body weight, and the mouse dose is set at 3.2g crude drug / kg, which is 8 times the proposed clinical dose. This is the clinical equivalent dose. Before the experiment, the basal body temperature is measured once and recorded as T0. The basal body temperature is screened and grouped. After the grouping is completed, the drug is administered. 30 minutes after the administration, the rats are intraperitoneally injected with 20μg / kg LPS. The rectal temperature is measured every 1h after modeling and recorded as T x , for 5 consecutive hours, calculate the body temperature difference △T, △T=T x -T0.

[0169] 2.4 Anti-inflammatory experiments

[0170] KM mice, half male and half female, were randomly divided into 6 groups according to body weight, namely model group, aspirin group, Lianhua Qingwen group, Chinese medicine composition of the present invention (LHQG) group, comparative example 1 (LHQG-A) group, and comparative example 2 (LHQG-B) group. The proposed clinical dose is 0.4g crude drug / kg body weight, and the mouse dose is set at 4.0g crude drug / kg, which is 10 times the proposed clinical dose, which is the clinical equivalent dose. The drug was administered continuously for 3 days, once / d. About 0.5h after the last administration, xylene was applied to the middle of the right ear of the mouse, 15μl on each side, and the left ear was not treated. After 40min, the animal was killed by cervical dislocation, and the ear punch was used to punch the ear pieces at the symmetrical parts of the two ears. The ears were weighed with a precision analytical balance, the weight was recorded, and the swelling degree and swelling inhibition rate were calculated. Swelling degree = weight of the right ear piece - weight of the left ear piece. Swelling inhibition rate = (average swelling degree of the model group - average swelling degree of the drug-treated group) / average swelling degree of the model group × 100%.

[0171] 3 Statistical methods

[0172] The experimental data are expressed as mean ± standard deviation The test level was 0.05 and 0.01. SPSS software was used for statistical analysis. One-way analysis of variance was used for comparison of means. The homogeneity of variance was tested first. If the variances were homogeneous, the least significant difference (LSD) method was used. If the variances were unequal, the Dunnett's T3 test was used.

[0173] 4 Results

[0174] 4.1 Antitussive test

[0175] Compared with the model group, the cough incubation period of mice in the Lianhua Qingwen group and the Chinese medicine composition of the present invention (LHQG) group was significantly prolonged (P<0.05), and the number of coughs was significantly reduced (P<0.05). There was no significant difference in the cough incubation period and number of coughs between the mice in the control group 1 (LHQG-A) group and the control group 2 (LHQG-B) group (P>0.05). The cough incubation period of mice in the dextromethorphan group was significantly prolonged (P<0.05), and the number of coughs was significantly reduced (P<0.05) compared with the model group.

[0176] Table 1 Test results of the effects of the drugs of the present invention on ammonia-induced cough in mice

[0177]

[0178] Note: Compared with the model group: *P<0.05.

[0179] 4.2 Expectorant test

[0180] Compared with the model group, the phenol red concentration of mice in the Lianhua Qingwen group and the LHQG group was significantly increased (P<0.05), while there was no significant difference in the phenol red concentration of mice in the LHQG-A group and the LHQG-B group (P>0.05); the phenol red concentration of mice in the ambroxol group was significantly increased compared with the model group (P<0.05).

[0181] Table 2 Effect of the drugs of the present invention on phenol red secretion in mouse trachea

[0182]

[0183] Note: Compared with the model group: *P<0.05.

[0184] 4.3 Antipyretic test

[0185] Compared with the model group, the body temperature differences of the rats in the Lianhua Qingwen group and the LHQG group were significantly reduced 3h and 4h after modeling (P<0.05), while no significant difference was found in the body temperature differences of the rats in the LHQG-A group and the LHQG-B group after modeling (P>0.05). The body temperature differences of the rats in the ibuprofen group were significantly reduced 2h, 3h, and 4h after modeling compared with the rats in the model group (P<0.01 or P<0.05).

[0186] Table 3 Test results of the effects of the drugs of the present invention on LPS-induced fever in rats

[0187]

[0188] Note: Compared with the model group: **P<0.01, *P<0.05.

[0189] 4.4 Anti-inflammatory experiments

[0190] Compared with the model group, ear swelling in the Lianhua Qingwen and LHQG groups was significantly reduced (P<0.05), with swelling inhibition rates of 30.29% and 30.85%, respectively. No significant difference in ear swelling was observed between the LHQG-A and LHQG-B groups (P>0.05). Ear swelling in the aspirin group was significantly reduced (P<0.01), with a swelling inhibition rate of 37.70%.

[0191] Table 4 Test results of the effects of the drugs of the present invention on xylene-induced ear swelling in mice

[0192]

[0193] Note: Compared with the model group: **P<0.01, *P<0.05.

[0194] 5 Conclusion

[0195] Under the experimental conditions, LHQG significantly inhibited ammonia-induced coughing in mice, significantly increased phenol red excretion in the mouse trachea, significantly suppressed LPS-induced fever in rats, and significantly reduced xylene-induced ear swelling in mice, demonstrating efficacy comparable to Lianhua Qingwen. LHQG-A and LHQG-B showed no significant efficacy.

[0196] Test Example 3

[0197] In order to illustrate the analgesic effect of the Chinese medicine composition of the present invention, the following efficacy test was carried out using the granules prepared in Example 1 (hereinafter referred to as the Chinese medicine composition of the present invention (LHQG)).

[0198] 1. Purpose of the study

[0199] In this experiment, 0.7% acetic acid was intraperitoneally injected to induce writhing reaction in mice, and the effect of the Chinese medicinal composition of the present invention on pain was observed.

[0200] 2. Test methods

[0201] 1) Dosage and grouping

[0202] Sixty KM mice were randomly divided into five groups according to their body weight, including model group; indomethacin group; high-, medium- and low-dose LHQG groups. The doses of LHQG were 2.00, 1.00 and 0.50 g / kg, respectively. The indomethacin dose for mice was set at 5.00 mg / kg.

[0203] 2) Method of administration

[0204] The drug was administered orally, which is consistent with the intended clinical route of administration. The drug was administered using a disposable syringe at a volume of 10 ml / kg. The model group animals were given a corresponding volume of solvent for 5 consecutive days.

[0205] 3) Observation indicators, time and content

[0206] Newly received experimental animals were numbered, acclimated for 5 days, and grouped as described above. All animals were fasted for at least 15 hours before the final administration. One hour after the final administration, 10 ml / kg of 0.7% acetic acid was injected into the peritoneal cavity of the mice. This stimulated the visceral and parietal peritoneum, causing a deep, extensive, and prolonged pain response. This resulted in writhing behaviors such as abdominal indentation, extension of the trunk and hind limbs, and elevation of the buttocks. The latency to onset of the writhing response and the number of writhings within 15 minutes were recorded as quantitative pain indicators.

[0207] 4) Statistical methods

[0208] The experimental data were analyzed and processed using SPSS 18.0 statistical software, with a test level of 0.05 and 0.01. The results are expressed as mean ± standard deviation (±s). Normality was first tested. For data that met the normal distribution, means were compared using one-way analysis of variance (ANOVA). If the variances were equal, pairwise comparisons were performed using the least significant difference (LSD) method. If the variances were unequal, pairwise comparisons were performed using the Dunnett's T3 test. If the data did not meet the normal distribution, nonparametric tests were used.

[0209] 3. Results

[0210] As shown in Table 5, compared with the model group, the number of writhing events in the indomethacin group was significantly reduced (P < 0.05). The writhing latency of the mice in the medium-dose LHQG group was significantly prolonged (P < 0.05), and the number of writhing events was significantly reduced (P < 0.05). The writhing latency of the mice in the indomethacin and high-dose LHQG groups was slightly prolonged compared with the model group, but no significant difference was observed (P > 0.05). The number of writhing events in the high- and low-dose LHQG groups was reduced compared with the model group, but no significant difference was observed (P > 0.05).

[0211] Table 5 Test results of the effect of the Chinese medicine composition of the present invention on acetic acid-induced writhing in mice

[0212]

[0213] Note: Compared with the model group: **P<0.01, *P<0.05.

[0214] 4. Conclusion

[0215] Under the experimental conditions, LHQG can significantly inhibit the pain response induced by acetic acid stimulation of the mouse peritoneum, indicating that the Chinese medicine composition of the present invention has an analgesic effect and can be used to prepare analgesic drugs.

[0216] Test Example 4

[0217] In order to illustrate the clinical effectiveness of the Chinese medicine composition of the present invention, a clinical study was conducted using the granules prepared in Example 1 (hereinafter referred to as the Chinese medicine composition of the present invention).

[0218] 1 General Information

[0219] Patients diagnosed with childhood influenza who were admitted to the respiratory outpatient clinic or pediatrics department of Hebei Yiling Hospital were selected, and 101 patients who met the inclusion criteria were screened and randomly assigned to the drug group of the present invention and the western medicine control group for 5 consecutive days.

[0220] 2 Selection of research subjects

[0221] 2.1 Western medicine diagnostic criteria

[0222] Refer to the "Guidelines for Diagnosis and Treatment of Influenza (2011 Edition)" formulated by the Ministry of Health

[0223] 1. Clinical conditions that require consideration of influenza: (1) During the influenza epidemic, if one of the following conditions occurs, it is necessary to consider whether it is influenza: 1. Fever accompanied by acute respiratory symptoms such as cough and / or sore throat. 2. Fever accompanied by acute exacerbation of existing chronic lung disease. 3. Infants and children have fever without other symptoms and signs. 4. Elderly people (aged ≥ 65 years) have new respiratory symptoms, or worsening of existing respiratory symptoms, with or without fever. 5. Severely ill patients have fever or hypothermia. (2) At any time, fever accompanied by acute respiratory symptoms such as cough and / or sore throat, and an epidemiological history related to influenza can be traced - such as the patient has been to a unit or community with an influenza outbreak within 7 days before the onset of the disease; lived with or had close contact with a suspected influenza case; returned from a trip to a country or region where influenza is prevalent, etc.

[0224] 2. Cases Requiring Pathologic Testing: If conditions permit, pathologic testing may be performed for cases presenting with the above conditions to confirm the diagnosis. For cases where a definitive diagnosis will impact clinical management, Pathologic testing should be proactively arranged. These cases generally include: high-risk cases requiring a decision on whether to promptly initiate antiviral treatment; cases where a confirmed diagnosis impacts the scheduling of other diagnostic tests; cases requiring a decision on whether to administer antibiotics; cases awaiting diagnostic results to implement infection control measures; and cases undergoing epidemiological sampling surveys.

[0225] III. Diagnostic Criteria: Patients with clinical manifestations and positive results for one or more of the following pathogenic tests can be diagnosed with influenza: (1) Positive influenza virus nucleic acid test (real-time RT-PCR and RT-PCR methods can be used). (2) Positive influenza virus rapid antigen test (immunofluorescence and colloidal gold methods can be used), which must be combined with epidemiological history for comprehensive judgment. (3) Positive influenza virus isolation and culture. (4) A 4-fold or greater increase in influenza virus-specific IgG antibody levels in both acute and convalescent serum samples.

[0226] 2.2 TCM syndrome diagnostic criteria

[0227] The diagnosis and treatment of traditional Chinese medicine compound preparations should adhere to the basic principle of "corresponding prescription to syndrome" and use recognized syndrome diagnostic criteria. The "Guiding Principles for Clinical Trials of New Traditional Chinese Medicines for the Treatment of Influenza" points out that the more common TCM syndromes of influenza are mainly wind-heat invading the defensive qi, wind-cold binding the exterior, exterior cold and interior heat, and damp-heat stagnation. The drug of this invention is mainly suitable for heat-toxic lung syndrome (Influenza Diagnosis and Treatment Program (2018 Edition)). Symptoms include fever or high fever, aversion to cold, muscle aches, nasal congestion and runny nose, cough, headache, dry and sore throat, reddish tongue, yellow or greasy tongue coating, and slippery and rapid pulse.

[0228] 2.3 Inclusion criteria

[0229] 1. Meet the diagnostic criteria for influenza, have clinical manifestations of influenza, and have at least one respiratory symptom caused by influenza virus infection (cough, runny nose / nasal congestion, red and swollen throat, etc.). And the influenza symptoms started within 48 hours before enrollment in the study. 2. Age 3-14 years old, both male and female. 3. During the influenza season, body temperature ≥ 37.3℃ or a history of fever with body temperature ≥ 37.3℃ within 48 hours before baseline. 4. Did not take any antiviral / anti-influenza drugs after onset of the disease. 5. Positive influenza virus rapid antigen test of nasal or pharyngeal swab. 6. Before the start of the study, the legal guardian voluntarily signed a written informed consent (at the same time, children aged ≥ 10 years old need to voluntarily sign the informed consent).

[0230] 2.4 Exclusion criteria

[0231] 1. Patients with severe influenza and influenza with complications. 2. Fever ≥ 39.5℃. 2. Subjects with the following conditions: lower respiratory tract infections caused by non-influenza viruses, asthma requiring daily treatment, any other chronic respiratory diseases, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis, and other respiratory diseases that affect the evaluation of clinical trials. 3. Subjects have received influenza vaccines within 1 month; are receiving systemic hormones or other immunosuppressants, or are taking traditional Chinese medicine or other antiviral drugs. 4. Those with severe liver, kidney, heart, lung, vascular, nervous, endocrine, immune function diseases, or cancer. 5. Participated in other clinical trials in the past month. 6. Allergies or a known history of allergies to the components of the trial drugs. 7. Any other relevant diseases or conditions that the researcher believes may limit or hinder study participation or affect study results.

[0232] 2.5 Subject Exit Criteria

[0233] 2.5.1 Investigator's Decision: 1. The investigator determines that complications or physiological abnormalities render the subject no longer eligible for participation in the clinical trial. 2. The subject has taken less than 80% or more than 120% of the trial drug. 3. The subject experiences a serious adverse event and / or laboratory abnormality, and the investigator, in their sole discretion and / or for safety reasons, requests the subject to withdraw from the study. 4. The subject has taken medication prohibited by the trial protocol.

[0234] 2.5.2 Decisions by Subjects: Subjects may withdraw from the study at any time, with or without reason, and if a subject stops taking medication or refuses to undergo examinations, it is considered that the study has been discontinued. The study medical records of all subjects who withdraw from the study or discontinue the study should be fully recorded, and the last observed data should be used for efficacy and safety analysis.

[0235] 3 Treatment methods

[0236] (1) Grouping: The patients were divided into the drug group of the present invention and the western medicine control group (oral oseltamivir granules). The patients who met the inclusion and exclusion criteria were randomly assigned to the above two groups.

[0237] The drug group of the present invention: the granules prepared in Example 1 were taken for 5 days.

[0238] The Western medicine control group received oral oseltamivir granules, 25 mg / bag, for 5 days, taken with warm water. The recommended dosage for children is based on the following weight-based dosage chart (Table 6).

[0239] Table 6 Oseltamivir granules body weight-recommended dosage table

[0240] Recommended dose (5 days): ≤ 15 kg 30 mg twice daily; > 15-23 kg 45 mg twice daily; > 23-40 kg 60 mg twice daily; > 40 kg 75 mg twice daily

[0241] (2) Provisions for combined medication: During the trial, the protocol prohibits the use of any other drugs for the treatment of influenza and its related symptoms, including but not limited to antiviral drugs, antipyretic analgesics and any traditional Chinese medicine antiviral drugs. Any other drugs that the researcher believes may affect the trial are also not allowed to be used. In addition, during the trial, according to the following actual conditions, (1) if the subject's body temperature is ≥38.5℃, or the body pain (headache, sore throat, muscle aches) is unbearable, ibuprofen or paracetamol may be given for treatment. (2) if the subject has a severe cough, cough suppressants and expectorants will be given. (3) if the subject has signs of bacterial infection, antibacterial drugs will be given, and all medications must be recorded.

[0242] 4 Observation items and indicators

[0243] 4.1 Demographic Data

[0244] Including age, gender, height, weight, past medical history, current medical history, and allergy history.

[0245] 4.2 Safety Observation

[0246] General physical examination items,

[0247] Routine blood test (white blood cell count, neutrophil count, lymphocyte count, red blood cell count, hemoglobin, platelet count), routine urine test (urine protein, red blood cells (high-power microscopy), white blood cells (high-power microscopy)), liver and kidney function test (alanine aminotransferase, aspartate aminotransferase, total bilirubin, γ-glutamyl transpeptidase, alkaline phosphatase, urea nitrogen, creatinine), and electrocardiogram.

[0248] 4.3 Observation of therapeutic efficacy

[0249] Main indicator: Antipyretic effectiveness.

[0250] Secondary indicator: clinical efficacy.

[0251] Efficacy records: (1) Recording the course of disease: All parents of the subjects were trained by a dedicated person at the time of enrollment. Starting from the first day of enrollment, parents filled out a symptom diary card every day to record influenza-related symptom scores, body temperature, adverse reactions, secondary diseases, and concomitant medications.

[0252] 4.4 Criteria for determining efficacy

[0253] 4.4.1 Criteria for Determining Fever-Reducing Efficacy: Cured: The child's body temperature returns to normal within 24 hours after taking the medication, and there is no recurrence; Markedly Effective: The child's body temperature decreases by 1.0°C or more within 24 hours after taking the medication, but the temperature has not fully returned to normal; Effective: The child's body temperature decreases by 0.5 to <1.0°C within 24 hours after taking the medication, and the temperature has not fully returned to normal; Ineffective: The child's body temperature decreases by <0.5°C within 24 hours after taking the medication. Total Effective Rate = (Number of Cured Cases + Number of Markedly Effective Cases) / Total Number of Cases × 100%.

[0254] 4.4.2 Clinical efficacy assessment criteria refer to the "Guiding Principles for Clinical Research of New Traditional Chinese Medicines" and are based on influenza symptom scores. Cured: Clinical symptoms and signs disappear or essentially disappear after treatment, with a ≥95% reduction in influenza symptom score; Markedly effective: Flu symptom score reduction <95% and ≥70% after treatment; Effective: Flu symptom score reduction <70% and ≥30% after treatment; Ineffective: Flu symptom score reduction <30% after treatment. Total effective rate = (number of cured cases + number of markedly effective cases) / total number of cases × 100%. The symptom score table is shown in Table 7.

[0255] Table 7 Symptom score table

[0256]

[0257]

[0258] 5 Statistics

[0259] After the trial, professional statisticians conducted statistical analysis. Patients who did not meet the inclusion criteria, did not use the prescribed medication, or had severely incomplete data were excluded as ineligible cases and not included in the statistical analysis. The t-test was used as the statistical method. Finally, based on the statistical results, an objective evaluation of the efficacy of the proposed formula in treating influenza in children was made and a summary report was prepared.

[0260] 6 Results

[0261] 6.1 Antipyretic efficacy results

[0262] The total effective rate of the present invention in reducing fever in treating influenza in children reached 96.1%, which was much higher than the 74.0% of the Western medicine control group. In addition, the present invention had no effect on the antipyretic effect in only 2 patients, while the number of ineffective patients in the Western medicine control group reached 13. At the same time, the number of patients who recovered or showed significant improvement with the present invention's antipyretic effect reached 38, while the number in the Western medicine control group was only 23. From the above test results, it can be seen that the present invention has a better antipyretic effect than the Western medicine control group. The specific results are shown in Table 8 below:

[0263] Table 8 Antipyretic test results

[0264] Group Number of cases Cured Significantly effective Effective Ineffective Total effective rate Traditional Chinese medicine composition group 51122611296.1% Western medicine control group 50815141374.0%

[0265] 6.2 Clinical Efficacy Results

[0266] The total effective rate of the clinical efficacy of the drug of the present invention in treating influenza in children reached 98%, which was much higher than the 84% of the Western medicine control group. In addition, the clinical efficacy of the drug of the present invention in treating influenza in children was ineffective in only one patient, while the number of ineffective cases in the Western medicine control group reached 8. At the same time, the number of patients who recovered or showed significant improvement in the antipyretic effect of the drug of the present invention reached 43, while the number in the Western medicine control group was only 22. From the above test results, it can be seen that the drug of the present invention has a very good therapeutic effect compared with the Western medicine control group. The specific results are shown in Table 9 below:

[0267] Table 9 Clinical trial results

[0268] Group Number of cases Cured Significantly effective Effective Ineffective Total effective rate Chinese medicine composition group 5111327198% Western medicine control group 5051720884%

[0269] 6.3 Safety evaluation results

[0270] During the trial, two adverse events occurred, two of which occurred in the Western medicine control group. These events were related to the test drug and did not cause any health damage to the subjects. Patients in the group receiving the Chinese herbal composition of the present invention experienced no adverse reactions such as nausea, diarrhea, vomiting, abdominal pain, abdominal distension, dry mouth, rash, itching, or dizziness, nor did they experience any other adverse events. Furthermore, no laboratory abnormalities related to the drug of the present invention or clinically significant adverse medical events were observed, demonstrating the good safety of the Chinese herbal composition of the present invention.

[0271] Test Example 5

[0272] To illustrate the in vitro antiviral activity of the Chinese herbal composition of the present invention, the following test was conducted using the granules prepared in Example 1 (hereinafter referred to as the Chinese herbal composition of the present invention (LHQG)).

[0273] 1. Purpose of the experiment

[0274] By screening the efficacy of the Chinese medicine composition of the present invention against different respiratory tract infection viruses, its broad-spectrum antiviral activity and the efficacy mechanism of the Chinese medicine composition of the present invention in inhibiting influenza A virus replication in vitro were clarified.

[0275] 2. Experimental Materials

[0276] ①Strain and cell source:

[0277] Table 10 Virus strains and cell sources

[0278] Strain and cell name source A / PR / 8 / 34(H1N1)ATCC A / Aichi / 2 / 68(H3N2)ATCC A / GZ / GIRD / 07 / 2009(H1N1) clinical isolate from our laboratory B / Lee / 1940(FluB)ATCC A / Chicken / Guangdong / 1996 / (H9N2) gifted by a peer A / Chicken / Guangdong / 1996 / (H6N2) gifted by a peer A / Chicken / Guangdong / 1996 / (H7N3) gifted by a peer human rhinovirus (hRHV) gifted by a peer respiratory syncytial virus (RSV)ATCC human adenovirus (ADV3)ATCC Herpesvirus (HSV-1) clinical isolate from our laboratory Enterovirus 71 (EV71) ATCC ChCoV-229E laboratory-stored MDCK (canine kidney cells) ATCC Hep-2 (human laryngeal carcinoma epithelial cells) ATCC Huh-7 (human hepatocellular carcinoma cells) laboratory-stored

[0279] Vero (African green monkey kidney cells), ATCC A549 (human lung cancer cells), laboratory-maintained, RAW 264.7 (mouse mononuclear macrophage leukemia cells), laboratory-maintained, MRC-5 (human embryonic lung fibroblast cells), a gift from a colleague

[0280] ②Drug source

[0281] 1) Source of test drug and dissolution method

[0282] 1225 mg of the granules prepared in Example 1 were weighed and dissolved in 20 ml of DMSO. Ultrasonic heating was used to assist dissolution (20,000 Hz, 50°C water bath ultrasound for 1 h). After ultrasound, centrifugation was performed at 2000 RPM at room temperature for 15 min. The precipitate was discarded and the supernatant was aliquoted into 500 μl tubes and frozen at -20°C until use. The drug storage concentration was 61.25 mg / ml.

[0283] 2) Source of positive drugs

[0284] Table 11 Sources of positive drugs

[0285] Positive drug name Source Batch number Ribavirin MedchemExpress #11970 Abidol Shijiazhuang No. 4 Pharmaceutical Co., Ltd. 0802YZ

[0286] 3. Experimental Methods

[0287] ① Determination of the virus tissue infectious dose (TCID 50)

[0288] Host cells were seeded into 96-well plates. After the cells formed a monolayer, the culture medium was discarded and the cell surface was washed twice with PBS. Different concentrations of virus dilutions were added and the cells were incubated in a CO2 incubator for 48–72 hours. Cell growth was observed daily. If cells showed signs of CPE (cell shriveling, rounding, or detachment), the occurrence of CPE was recorded.

[0289] ②LHQG in vitro toxicity assay (MTT method)

[0290] Cells were seeded in a 96-well plate. A blank control group (medium alone, no cells) and a normal cell control group (drug dissolution medium) were also set up. Incubate for 48 hours, then continue incubation for another 4 hours. The culture was terminated, and 100 μL of DMSO was added to each well. The plates were shaken at low speed for 10 minutes. The OD value of each well was measured at a wavelength of 490 nm using a full-wavelength scanner. The TC50 of the drug was calculated.

[0291] ③ In vitro anti-influenza virus spectrum activity screening

[0292] Drug to be tested is carried out antiviral activity detection with the cell pathological effect inhibition method. With the culture medium containing 1ug / mL TPCK (trypsin), drug to be tested is diluted to eight concentrations, and the positive drug (ribavirin) doubling dilution is made into eight concentrations. MDCK cells are inoculated into 96 orifice plates, and after cells grow into monolayer, culture fluid is discarded and cell surface is washed 2 times with PBS. Normal cell control group, virus control group, drug control group are set, and virus liquid is discarded after hatching 2 hours in the incubator, and the culture medium containing drug to be tested and positive drug is added, and hatched 48 hours in the incubator, and observed and recorded cytopathic effect every day. The pathological degree that occurs in the cell is recorded by the 6 grades of standards in the following table 12.

[0293] Table 12 Six-level standard for virus-induced cytopathic effect (CPE)

[0294]

[0295] ④ In vitro screening of antiviral activity

[0296] The antiviral activity of the test drug was detected by cytopathic inhibition method. The test drug was diluted into eight concentrations with culture medium, and the positive drugs (ribavirin and arbidol) were diluted into eight concentrations. The host cells were inoculated into a 96-well plate. After the cells grew into a monolayer (about 24h), the culture medium was discarded and the cell surface was washed twice with PBS. 100uL / well of virus dilution solution was added, 4 replicates for each concentration, and normal cell control group, virus control group and drug control group were set up at the same time. The cells were incubated in an incubator. After 2 hours, the virus solution was discarded, and the culture medium containing the test drug and the positive drug was added. The cells were incubated in an incubator for 48 to 72 hours, and the cell pathological changes were observed and recorded every day. The degree of cell pathology was recorded according to the 6-level standard (see Table 12).

[0297] ⑤ Inhibit the expression of host inflammatory factors induced by influenza virus (A / PR / 8 / 34, H1N1) and lipopolysaccharide (LPS) in vitro

[0298] A549 cells with moderate growth density were inoculated into 6-well cell culture plates. After 48 hours, the supernatant culture medium was discarded, the cells were washed twice, 1 ml of influenza A virus culture medium was added, and the cells were placed in an incubator for adsorption for 2 hours. The supernatant was discarded, and the culture medium containing the drug to be tested was added. After 24 hours, the supernatant was discarded, the cells were washed twice, and the reagent was added to lyse the cells. The samples were used for subsequent RNA extraction. A virus infection control group, different doses of the drug to be tested intervention groups, and a non-infection drug control group were set up.

[0299] Macrophages with moderate growth density were inoculated onto cell culture plates. After 48 hours, the supernatant culture medium was discarded, the cells were washed, and serum-free culture medium was switched for starvation for 24 hours. On the third day, lipopolysaccharide and culture medium with different drug doses were added. After 24 hours, the cells were lysed and the samples were used for subsequent RNA extraction. The experimental groups included: model group, drug intervention group, and drug control group.

[0300] RT-PCR was used to detect the effect of the Chinese medicinal composition of the present invention on the expression level of host cell infection-related inflammatory factor mRNA.

[0301] ⑥LHQG action phase experiment

[0302] MDCK cells were inoculated into 12-well plates and grown to a monolayer. The culture supernatant was removed and washed twice with PBS. Then, influenza A virus A / PR / 34 strain was added for adsorption for 2 hours at 4°C. Viruses that had not yet adsorbed to the host cells were removed. Then, culture medium was added and incubated in an incubator. Drugs were added after infection and at designated time points after infection. After 10 hours, the 12-well plates were repeatedly frozen and thawed 3 times, and samples at each time point were collected for progeny virus titer determination (TCID 50 ).

[0303] ⑦Indirect immunofluorescence assay (influenza virus NP protein expression)

[0304] MDCK cells were seeded onto 8-well glass slides. When the cells reached approximately 40% growth, the culture medium was discarded and the cells were washed with PBS. After virus incubation, the cell nuclei were stained with DAPI-containing glycerol mounting solution and observed under a fluorescence microscope.

[0305] 4. Statistical methods

[0306] The experimental results reported in this report were statistically analyzed using SPSS 20.0 software, and graphs were generated using GraphPad Prism 5 software. All data were calculated using mean and standard deviation. Two-group comparisons were performed using the t-test, and multiple-group comparisons were performed using one-way ANOVA. Pairwise comparisons were performed using the LSD method assuming homogeneity of variance, and using the Tamhane's T2 or Dunnett's T3 test if heterogeneity of variance was assumed. For multiple-group measurement data that did not conform to a normal distribution and homogeneity of variance, the Kruskal-Wallis rank sum test was used. P < 0.05 was considered statistically significant.

[0307] 5. Results

[0308] ① The median infectious dose of the virus (TCID 50 )result:

[0309] 48 to 72 hours after virus inoculation into corresponding host cells, CPE was observed under a microscope and TCID was calculated according to the Reed-Muench method. 50 , as shown in Table 13 below.

[0310] Table 13 Virus strain TCID 50 Determination

[0311]

[0312] ②LHQG in vitro toxicity assay (MTT method)

[0313] The cytotoxicity of LHQG to cells (MDCK, Hep-2, Huh-7, MRC-5, Vero) in vitro was tested by MTT assay, and the TC was calculated according to the Reed-Muench method. 50 , see Figure 1 for details.

[0314] ③LHQG in vitro antiviral spectrum screening (CPE method)

[0315] The in vitro antiviral activity of LHQG was tested by cytopathic inhibition assay, and the IC was calculated according to the Reed-Muench method. 50 The results are shown in Tables 14 and 15.

[0316] Table 14 Antiviral efficacy of LHQG

[0317]

[0318] Table 15 Antiviral spectrum efficacy of positive drugs

[0319]

[0320] ④Effect of LHQG on influenza virus and lipopolysaccharide-induced cytokine mRNA expression levels

[0321] The results of RT-PCR experiments showed that compared with the virus infection model group, LHQG can significantly reduce the expression of influenza virus-induced host cell inflammatory factors MIP-1β, IFN-β, IP-10, IL-6, CCL5, MCP-1, TNF-α, RIG-I, MIG, and CXCL1 mRNA levels, as shown in Table 16 below (Note: *P<0.05, **P<0.01, ***P<0.001).

[0322] Table 16 LHQG inhibits influenza virus-induced host cell inflammatory factor expression

[0323]

[0324] At the same time, LHQG can reduce the expression of inflammatory factors IL-6, TNF-α, IP-10, MCP-1, and IL-1β in host cells stimulated by lipopolysaccharide in a dose-dependent manner. See Table 17 below for details (Note: *P<0.05, **P<0.01).

[0325] Table 17 Effects of LHQG on mRNA expression levels in host cells stimulated by lipopolysaccharide

[0326]

[0327] Note: Comparison between drug-treated group and LPS control group: *P<0.05, **P<0.01

[0328] ⑤LHQG anti-influenza virus action phase

[0329] LHQG was added at time points (0, 2, 4, 6, and 8 hours) during a single influenza virus replication cycle. Samples were collected at each time point, along with samples from the virus-infected control group. The results showed that LHQG significantly reduced viral titers (P < 0.01 or P < 0.001) when added between 0 and 4 hours (early stages of viral replication). This suggests that LHQG has an antiviral effect, primarily at the early stages of viral replication. See Table 18 for details (Note: ** indicates P < 0.01, *** indicates P < 0.001).

[0330] Table 18 Phase data of LHQG anti-influenza virus effect

[0331]

[0332] Note: Comparison between drug-treated group and virus control group: **P<0.01, ***P<0.0001

[0333] ⑥ Indirect immunofluorescence assay (influenza virus NP protein expression assay)

[0334] Host cells were infected with the virus (0h, 2h, 4h, 6h, 8h), and LHQG was added for intervention. The cells were taken for immunofluorescence experiments and observed under a fluorescence microscope. The results showed that the addition of LHQG intervention after virus infection (0h) could significantly reduce the expression of NP protein of influenza virus, as shown in Figure 2 for details.

[0335] 6. Conclusion

[0336] The traditional Chinese medicine composition (LHQG) of the present invention exhibits in vitro antiviral effects against multiple strains of influenza A and B viruses, respiratory syncytial virus, and coronavirus. LHQG exhibits broad-spectrum antiviral activity in vitro, acting at the early stages of viral replication. Furthermore, the composition significantly reduces the expression of host cell inflammatory factors induced by influenza viruses and LPS, demonstrating a clear in vitro anti-inflammatory effect.

[0337] Test Example 6:

[0338] To illustrate the antiviral activity of the Chinese medicinal composition of the present invention, the following test was conducted using the granules prepared in Example 1 (hereinafter referred to as the Chinese medicinal composition of the present invention).

[0339] 1 Experimental Purpose

[0340] In this study, BALB / c mice were infected with influenza A virus (H3N2) and respiratory syncytial virus (RSV) by intranasal drip to establish influenza A virus and RSV animal models. The effects of the Chinese herbal composition of the present invention on the clinical symptoms (body weight, lung index, cytokines) and pathogen-related indicators (viral load) of infected mice were observed to screen for the most effective formulation of the Chinese herbal composition of the present invention (LHQG).

[0341] 2 Experimental methods

[0342] 2.1 In vivo pharmacodynamic studies against influenza A virus

[0343] SPF BALB / c mice, half male and half female, weighing 17.0-20.0 g, were randomly divided into seven groups according to sex and weight: normal control, model control, oseltamivir phosphate capsule, Lianhua Qingwen, LHQG, LHQG-A, and LHQG-B. The proposed clinical dose of LHQG, LHQG-A, and LHQG-B is 0.4 g of crude drug / kg body weight. The mouse dose was 4.0 g of crude drug / kg, 10 times the proposed clinical dose and the clinical equivalent dose. Each treatment group was orally administered with the corresponding drug concentration at 10 mL / kg by gavage. The normal and model control groups were given an equal volume of purified water once daily for seven consecutive days. On day 4 of dosing (pre-dose), mice in each group were lightly anesthetized with ether and administered intranasally with 80 μL of H3N2 influenza A virus stock solution (hemagglutination titer of 6 log2 as determined by hemagglutination inhibition assay, pre-chilled at 4°C prior to intranasal administration). A normal control group received an equal volume of blank culture medium intranasally. Lungs were dissected and weighed 2 hours after the last dose, and lung index was calculated. Interleukin-1β and TNF-α levels in lung homogenates were measured by ELISA, and influenza virus load in the lungs was determined by quantitative PCR.

[0344] 2.2 In vivo pharmacodynamic studies against syncytial virus

[0345] SPF-grade BALB / c mice, half male and half female, weighing 17.0-20.0g, were randomly divided into seven groups according to sex and weight: normal control group, model control group, ribavirin tablet group, Lianhua Qingwen group, LHQG group, LHQG-A group, and LHQG-B group. The proposed clinical dose of LHQG, LHQG-A, and LHQG-B is 0.4g of crude drug / kg body weight. The mouse dose is 4.0g of crude drug / kg, which is 10 times the proposed clinical dose and the clinical equivalent dose. Each treatment group was orally administered with the corresponding concentration of drug solution at 10mL / kg by gavage. The normal control and model control groups were given an equal volume of purified water once daily for 7 consecutive days. On day 4 of dosing (pre-dose), mice in each group were lightly anesthetized with ether and injected intranasally with 80 μL of RSV virus solution (concentration: 100 TCID, pre-chilled at 4°C prior to intranasal instillation). The normal control group received an equal volume of blank culture medium. Lungs were dissected and weighed 2 hours after the last dose, and the lung index was calculated. Interleukin-1β and tumor necrosis factor-α levels in lung homogenates were determined by ELISA, and influenza virus load in the lungs was determined by quantitative PCR.

[0346] 3 Statistical methods

[0347] The experimental data are expressed as mean ± standard deviation The test level was 0.05 and 0.01. SPSS software was used for statistical analysis. One-way analysis of variance was used for comparison of means. The homogeneity of variance was tested first. If the variances were homogeneous, the least significant difference (LSD) method was used. If the variances were unequal, the Dunnett's T3 test was used.

[0348] 4 Results

[0349] 4.1 In vivo pharmacodynamic studies against influenza A virus

[0350] Compared with the normal control group, the lung index in the model control group was significantly increased after viral infection (P<0.01), and the levels of inflammatory factors (IL-1β, TNF-α) and viral load in lung tissue homogenates were significantly increased (P<0.01). Compared with the model control group, the lung index, inflammatory factors in the lungs, and viral load in the Lianhua Qingwen and LHQG groups were significantly decreased (P<0.01 or P<0.05). No significant differences were found in the above indicators in the LHQG-A and LHQG-B groups (P>0.05). The lung index, inflammatory factor levels in the lungs, and viral load in the oseltamivir phosphate capsule group were significantly decreased (P<0.01 or P<0.05).

[0351] Table 19 Effects of H3N2 infection on lung index ( n=10)

[0352]

[0353] Note: Compared with the normal control group ++ P<0.01; compared with the model control group * P<0.05, ** P<0.01.

[0354] Table 20 Effects of H3N2 infection on IL-1β and TNF-α levels in the lungs ( n=10)

[0355]

[0356] Note: Compared with the normal control group ++ P<0.01; compared with the model control group * P<0.05, ** P<0.01.

[0357] Table 21 Effects of H3N2 infection on lung viral load ( n=10)

[0358]

[0359]

[0360] Note: Compared with the normal control group ++ P<0.01; compared with the model control group * P<0.05, ** P<0.01.

[0361] 4.2 In vivo pharmacodynamic studies against respiratory syncytial virus

[0362] Compared with the normal control group, the lung index in the model control group was significantly increased after viral infection (P<0.01), and the levels of inflammatory factors (IL-1β, TNF-α) and viral load in lung tissue homogenates were significantly increased (P<0.01). Compared with the model control group, the lung index, inflammatory factors in the lungs, and viral load in the Lianhua Qingwen and LHQG groups were significantly decreased (P<0.01 or P<0.05). No significant differences were found in the above indicators in the LHQG-A and LHQG-B groups (P>0.05). The lung index, inflammatory factor levels in the lungs, and viral load in the oseltamivir phosphate capsule group were significantly decreased (P<0.01 or P<0.05).

[0363] Table 22 Effects of respiratory syncytial virus infection on lung index ( n=10)

[0364]

[0365] Note: Compared with the normal control group ++ P<0.01; compared with the model control group * P<0.05, ** P<0.01.

[0366] Table 23 Effects of respiratory syncytial virus infection on IL-1β and TNF-α levels in the lungs ( n=10)

[0367]

[0368] Note: Compared with the normal control group ++ P<0.01; compared with the model control group * P<0.05, ** P<0.01.

[0369] Table 24 Effect on lung viral load of respiratory syncytial virus infection ( n=10)

[0370]

[0371] Note: Compared with the normal control group ++ P<0.01; compared with the model control group * P<0.05,** P<0.01.

[0372] 5 Conclusion

[0373] Under the experimental conditions, LHQG (a traditional Chinese medicine composition of the present invention) significantly reduced lung index, lung inflammatory factor levels, and viral load after influenza A virus and respiratory syncytial virus infection, with efficacy comparable to Lianhua Qingwen. LHQG-A and LHQG-B showed no significant antiviral efficacy.

[0374] Test Example 7

[0375] To further illustrate the antiviral activity of the Chinese medicinal composition of the present invention in vivo, the following test was conducted using the granules prepared in Example 1 (hereinafter referred to as the Chinese medicinal composition of the present invention).

[0376] 1. Purpose of the experiment

[0377] In this study, BALB / c mice were infected with influenza A virus (H3N2) and respiratory syncytial virus (RSV) by intranasal drip to establish influenza A virus and RSV animal models. The efficacy of the Chinese herbal composition (LHQG) of the present invention was evaluated by observing the effects of the composition on clinical symptoms and pathogenesis-related indicators of infected mice.

[0378] 2 Experimental methods

[0379] 2.1 In vivo pharmacodynamic studies against influenza A virus

[0380] A total of 140 SPF BALB / c mice, half male and half female, weighing 15.6-20.0 g, were randomly divided into 7 groups according to sex and weight, including normal control group, model control group, oseltamivir phosphate capsule group (20 mg / kg), Lianhua Qingwen capsule group (0.5 g / kg), and LHQG low-, medium-, and high-dose groups, with 20 mice in each group. LHQG was prepared daily with 0.5% sodium carboxymethylcellulose (CMC-Na) to concentrations of 0.05, 0.10, and 0.20 g powder / mL (the dosage in the subsequent experimental table is the raw drug dosage). Oseltamivir phosphate capsules were prepared with purified water to a concentration of 2 mg / mL, and Lianhua Qingwen capsules were prepared with purified water to a concentration of 0.05 g / mL. Mice in the low-, medium-, and high-dose LHQG, oseltamivir phosphate capsule, and Lianhua Qingwen capsule groups were orally gavaged at 10 mL / kg of the corresponding concentrations. The normal control group and the virus model group were given an equal volume of purified water once daily for 7 consecutive days. On the fourth day of administration (before administration), mice in each group were lightly anesthetized with ether. Except for the normal control group, mice in each group were nasally instilled with H3N2 influenza A virus solution (pre-cooled at 4°C before intranasal infection) at 80 μL / mouse. The normal control group was nasally instilled with an equal volume of blank culture medium.

[0381] On D5 (24 h after the poisoning) and D7 (2 h after the last administration), animals were randomly selected from each group, and the contents of IL-1β, TNF-α, INF-γ, and IL-10 in lung homogenates were detected by ELISA kits; the hemagglutination inhibition titer of the lung suspension was detected by hemagglutination inhibition test (the maximum dilution factor that completely inhibited the aggregation of red blood cells was the hemagglutination inhibition titer), and log2 (maximum dilution factor) was used to reflect the virus titer in the lung; HE staining and light microscopy were used to observe the pathological changes, and the lung pathological changes were comprehensively evaluated according to the pathological changes of alveolar structure, alveolar septum, pulmonary interstitium, bronchiolar mucosa and inflammatory cell infiltration (scoring was performed according to the degree of lesions, the scoring criteria are as follows: 0 point: normal; 1 point: very mild (lesions less than 10%); 2 points: mild (lesions 10% to 30%); 3 points: moderate (lesions 30% to 50%); 4 points: severe (lesions greater than 50%)); the CD4 + 、CD8 + Lymphocytes were immunohistochemically stained, and the fluorescence signals were analyzed using Image J software. + The cells showed red fluorescent signals, CD8 + The cells show green fluorescence signals, and the fluorescence value reflects the number of CD4+ and CD8+ cells, and the CD4 + / CD8 + ratio.

[0382] 2.2 In vivo pharmacodynamic studies against syncytial virus

[0383] Twenty-four SPF BALB / c mice, half male and half female, weighing 14.4-20.3 g, were randomly divided into seven groups according to sex and weight: a normal control group, a model control group, a ribavirin tablet group (60 mg / kg), a Lianhua Qingwen capsule group (0.5 g / kg), and low-, medium-, and high-dose LHQG groups, with 32 mice per group. LHQG was prepared daily with 0.5% sodium carboxymethylcellulose (CMC-Na) to concentrations of 0.05, 0.10, and 0.20 g powder / mL (the doses in the subsequent experimental tables are the raw drug amounts). Ribavirin tablets were prepared with purified water to a concentration of 6.0 mg / mL, and Lianhua Qingwen capsules were prepared with purified water to a concentration of 0.05 g / mL. Mice in each group were orally gavaged at 10 mL / kg of the corresponding concentrations. The normal control group and the virus model group were given an equal volume of purified water once daily for 7 consecutive days. On D4 (before administration), each group of mice was lightly anesthetized with ether. Except for the normal control group, each group of mice was nasally instilled with RSV virus stock solution (pre-cooled at 4°C before nasal infection), 80 μL / mouse. The normal control group was nasally instilled with an equal volume of blank culture medium.

[0384] On D5 (24 h after the poisoning) and D7 (2 h after the last administration), animals were randomly selected from each group, and the contents of IL-1β, TNF-α, INF-γ, and IL-10 in lung homogenate were detected by ELISA kits; the CD4 lymphocytes in whole blood were detected by flow cytometry. + 、CD8 + cells, count CD4 + 、CD8 + Flow cytometry was used to determine the CD4 lymphocytes in lung homogenate + 、CD8 + cells, macrophages (M1, M2), count CD4 + / CD8 + , M1 / M2; NK cells in the spleen were detected by flow cytometry; HE staining and light microscopy were used to observe pathological changes, and lung pathological changes were comprehensively evaluated according to the pathological changes of alveolar structure, alveolar septum, pulmonary interstitium, bronchiolar mucosa and inflammatory cell infiltration (scoring was based on the degree of lesions, the scoring criteria were as follows: 0 points: normal; 1 point: very mild (lesions less than 10%); 2 points: mild (lesions 10% to 30%); 3 points: moderate (lesions 30% to 50%); 4 points: severe (lesions greater than 50%)); CD4 + 、CD8 + Lymphocytes were immunohistochemically stained, and the fluorescence signals were analyzed using Image J software. + The cells showed red fluorescent signals, CD8 + The cells show green fluorescence signals, and the fluorescence value reflects the CD4 + 、CD8 + The number of cells and the calculation of CD4 + / CD8 + ratio.

[0385] 3 Statistical methods

[0386] SPSS statistical software was used. Measurement data were expressed as mean ± standard deviation (SD). Leven's test was used to test normality and homogeneity of variance. If the difference was not statistically significant (P>0.05), one-way analysis of variance (ANOVA) was used for statistical analysis. If the ANOVA was statistically significant (P≤0.05), the LSD test (parametric method) was used for comparative analysis. If the variance was not homogeneous (P≤0.05), the Kruskal-Wallis test was used. If the Kruskal-Wallis test was statistically significant (P≤0.05), the Dunnett's test (nonparametric method) was used for comparative analysis. Statistical results were tested with an α = 0.05 threshold, where P≤0.05 indicated statistical significance and P≤0.01 indicated highly significant differences.

[0387] 4 Results

[0388] 4.1 Results of in vivo pharmacodynamic studies against influenza A virus

[0389] 1) Effects on IL-1β, TNF-α, IL-10, and INF-γ levels in lung tissue

[0390] As shown in Table 25, 24 h after infection, the levels of IL-1β, TNF-α, IL-10, and INF-γ in the model control group were significantly increased compared with those in the normal control group (P≤0.05 or P≤0.01). Compared with the model control group, the IL-1β levels in the low-, medium-, and high-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group were significantly decreased (P≤0.05 or P≤0.01); the TNF-α levels in the medium-, high-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group were significantly decreased (P≤0.05 or P≤0.01), and the TNF-α level in the low-dose LHQG group showed a downward trend, but there was no statistical difference; the INF-γ level in the high-dose LHQG group was significantly decreased (P≤0.05 or P≤0.01), and the IL-10 levels in the low-, medium-, and high-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group; the INF-γ levels in the low-, medium-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group showed a downward trend, but there was no statistical difference. Two hours after the last dose, compared with the normal control group, the levels of IL-1β and TNF-α in the model control group were significantly increased (P ≤ 0.05 or P ≤ 0.01), while the levels of IL-10 and INF-γ showed an increasing trend, but no statistical difference was found. Compared with the model control group, the level of L-1β in the high-dose LHQG group and the Lianhua Qingwen capsule group was significantly decreased (P ≤ 0.01), while the level of L-1β in the low- and medium-dose LHQG groups and the oseltamivir phosphate capsule group showed a decreasing trend, but no statistical difference was found. The levels of TNF-α in the medium- and high-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group were all significantly decreased (P ≤ 0.05 or P ≤ 0.01), while the level of TNF-α in the low-dose LHQG group showed a decreasing trend, but no statistical difference was found. The levels of IL-10 and INF-γ in the low-, medium-, and high-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group all showed a decreasing trend, but no statistical difference was found.

[0391] Table 25 Effects on IL-1β, TNF-α, IL-10, and INF-γ levels in the lungs ( n=10)

[0392]

[0393] Note: Compared with the normal control group + P≤0.05; ++ P≤0.01; compared with the model control group * P≤0.05, ** P≤0.01.

[0394] 2) Effect on the hemagglutination titer of H3N2 influenza A virus in lung tissue

[0395] As shown in Table 26, the normal control group was not infected with influenza virus and had no viral titer in the lungs. Compared with the model control group, 24 hours after infection and 2 hours after the last dose, the viral hemagglutination titer in the lungs of the low-, medium-, and high-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group was significantly reduced (P ≤ 0.01).

[0396] Table 26 Effect on lung H3N2 influenza A virus hemagglutination titer ( n=10)

[0397]

[0398] Note: Compared with the normal control group ++ P≤0.01; compared with the model control group ** P≤0.01.

[0399] 3) Effects on pathological changes in lung tissue

[0400] As shown in Table 27 and Figures 3 and 4, Figure 3 shows the pathological effects of the lung tissue 24 hours after exposure: A, Normal control group; B, model control group; C, oseltamivir phosphate capsule group; D, Lianhua Qingwen capsule group; E, LHQG low-dose group; F, LHQG medium-dose group; G, LHQG high-dose group; black arrows indicate alveoli (B, D); blue arrows indicate pulmonary interstitium (B, C, D); red arrows indicate bronchioles (B, F). Figure 4 shows the results of the effect on lung tissue pathology 2 hours after the last administration: A, normal control group; B, model control group; C, oseltamivir phosphate capsule group; D, Lianhua Qingwen capsule group; E, LHQG low-dose group; F, LHQG medium-dose group; G, LHQG high-dose group; black arrows indicate alveoli (B, E); blue arrows indicate pulmonary interstitium (B, D, E); red arrows indicate bronchioles (B, C).

[0401] Twenty-four hours after exposure, the bronchi and alveoli in the normal control group showed clear structures and neatly arranged cells. In the model control group, the alveolar walls showed significant swelling, partial collapse, and rupture, the capillary bronchiolar walls thickened, and some mucosal cells shed, accompanied by a large infiltration of inflammatory cells. The low-, medium-, and high-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group showed significantly less lesions compared with the model control group, and the pathological scores were significantly reduced (P ≤ 0.05 or P ≤ 0.01). Two hours after the last dose, the bronchi and alveoli in the normal control group showed clear structures and neatly arranged cells. In the model control group, the alveolar walls showed partial collapse and rupture, the interstitial lung tissue thickened, and inflammatory cell infiltration was observed. Compared with the model control group, the low-, medium-, and high-dose LHQG groups, the oseltamivir phosphate capsule group, and the Lianhua Qingwen capsule group showed significantly less lesions compared with the model control group, and the pathological scores were significantly reduced (P ≤ 0.05 or P ≤ 0.01).

[0402] Table 27 Effects on lung tissue pathology ( n=10)

[0403]

[0404] Note: Compared with the normal control group ++ P≤0.01; compared with the model control group * P≤0.05, ** P≤0.01.

[0405] 4) CD4 + 、CD8 + The influence of lymphocytes

[0406] As shown in Table 28 and Figures 5 and 6, Figure 5 shows the CD4 + 、CD8 + The results of the influence of cell fluorescence intensity value: CD4 + 、CD8 + Signal merge diagram, A, normal control group; B, model control group; C, oseltamivir phosphate capsule group; D, Lianhua Qingwen capsule group; E, LHQG low-dose group; F, LHQG medium-dose group; G, LHQG high-dose group, Figure 6 shows the CD4 + 、CD8 + The results of the influence of cell fluorescence intensity value: CD4 + 、CD8 + Signal merge diagram, A, normal control group; B, model control group; C, oseltamivir phosphate capsule group; D, Lianhua Qingwen capsule group; E, LHQG low-dose group; F, LHQG medium-dose group; G, LHQG high-dose group.

[0407] 24h after exposure and 2h after the last administration, the number of CD4 + / CD8 + were significantly decreased (P≤0.01), suggesting that H3N2 influenza A virus infection can cause CD4 + 、CD8 + Compared with the model control, 24 hours after exposure and 2 hours after the last administration, the CD4 + / CD8 + were significantly increased (P≤0.01), indicating that oral administration of LHQG can improve the CD4 + 、CD8 + Lymphocyte imbalance.

[0408] Table 28 Pairs of lung tissue CD4 + / CD8 + Effect of immunohistochemical fluorescence intensity ratio ( n=6)

[0409]

[0410] Note: Compared with the normal control group ++ P≤0.01; compared with the model control group * P≤0.05, ** P≤0.01.

[0411] The above test results show that LHQG can reduce the lung index and reduce the H3N2 influenza A virus load in the lungs. At the same time, low, medium and high doses of LHQG can reduce the accumulation of inflammatory factors in the lungs, improve the pathological changes of lung tissue caused by the virus, and significantly increase the CD4 + / CD8 + In summary, LHQG has a significant anti-influenza A virus efficacy in vivo, which may be related to its ability to regulate local lung tissue immune cells and inhibit lung tissue inflammatory response.

[0412] 4.2 Results of in vivo pharmacodynamic studies against respiratory syncytial virus

[0413] 1) Effects on IL-1β, TNF-α, IL-10, and INF-γ levels in lung tissue

[0414] As shown in Table 29, 24 hours after exposure, the IL-1β, TNF-α, IL-10, and INF-γ levels in the model control group were significantly increased compared with the normal control group (P ≤ 0.01). Compared with the model control group, the IL-1β levels in the medium- and high-dose LHQG groups, the ribavirin tablet group, and the Lianhua Qingwen capsule group were significantly decreased (P ≤ 0.01). The IL-1β level in the low-dose LHQG group showed a downward trend, but there was no statistical difference. Compared with the model control group, the TNF-α, IL-10, and INF-γ levels in the low-, medium-, and high-dose LHQG groups, the ribavirin tablet group, and the Lianhua Qingwen capsule group were significantly decreased (P ≤ 0.05 or P ≤ 0.01). 2 hours after the last administration, compared with the normal control group, the IL-1β, TNF-α, and IL-10 levels in the model control group were significantly increased (P≤0.01), and the INF-γ level showed an increasing trend, but there was no statistical difference; compared with the model control group, the TNF-α and IL-10 levels in the low-, medium-, and high-dose LHQG groups, the ribavirin tablet group, and the Lianhua Qingwen capsule group were significantly decreased (P≤0.01); the IL-1β level in the low-, medium-, and high-dose LHQG groups, the ribavirin tablet group, and the Lianhua Qingwen capsule group was significantly decreased (P≤0.01), and the IL-1β level in the high-dose LHQG group showed a decreasing trend, but there was no statistical difference; compared with the model control group, the INF-γ levels in the low-, medium-, and high-dose LHQG groups, the ribavirin tablet group, and the Lianhua Qingwen capsule group showed a decreasing trend, but there was no statistical difference.

[0415] Table 29 Effects on IL-1β, TNF-α, IL-10, and INF-γ levels in the lungs ( n=10)

[0416]

[0417] Note: Compared with the normal control group + P≤0.05; ++ P≤0.01; compared with the model control group * P≤0.05, ** P≤0.01.

[0418] 2) CD4 + / CD8 + The influence of lymphocyte ratio

[0419] As shown in Table 30, compared with the normal control group, 24 hours after exposure and 2 hours after the last administration, the CD4 + / CD8 + 24h after the poisoning, compared with the model control group, the peripheral blood CD4 + / CD8+ The ratio increased significantly (P≤0.05), and the peripheral blood CD4 + / CD8 + The ratio showed an increasing trend, but there was no statistical difference; compared with the model control group, 24 hours after infection, the number of CD4 + / CD8 + The ratio was significantly increased (P≤0.05), and the CD4 + / CD8 + The ratio showed an increasing trend, but there was no statistical difference. 2 hours after the last administration, compared with the model control group, the peripheral blood CD4 + / CD8 + The ratio increased significantly (P≤0.05), and the peripheral blood CD4 + / CD8 + The ratio showed an increasing trend, but there was no statistical difference; 2 hours after the last administration, the number of CD4 + / CD8 + The ratio increased significantly (P≤0.05), and the CD4 + / CD8 + The ratio showed an increasing trend, but there was no statistical difference. The CD4 + / CD8 + There was no significant difference between the ratios in the model control group and those in the control group.

[0420] Table 30 CD4 + / CD8 + The effect of lymphocyte ratio ( n=6)

[0421]

[0422] Note: Compared with the normal control group + P≤0.05; ++ P≤0.01; *P≤0.05 compared with the model control group.

[0423] 3) Effects on lung macrophages and spleen NK cells

[0424] As shown in Table 31, compared with the normal control group, the M1 / M2 ratio of macrophages in the lung tissue of the model control group was significantly increased 24 hours after infection and 2 hours after the last administration (P≤0.01), and the NK cells in the spleen were significantly decreased 24 hours after infection (P≤0.05). 2 hours after the last administration, the NK cells in the spleen showed a decreasing trend, but there was no statistical difference. Compared with the model control group, 24 hours after infection, the M1 / M2 ratio in the lungs of the low-, medium-, and high-dose LHQG groups, and the ribavirin tablets group was significantly decreased (P≤0.05). 2 hours after the last administration, the M1 / M2 ratio in the lungs of the low-, medium-, and high-dose LHQG groups, the ribavirin tablets group, and the Lianhua Qingwen capsules group was significantly decreased (P≤0.05 or P≤0.01). Compared with the model control group, 24 hours after infection and 2 hours after the last administration, the NK cells in the spleens of the low-, medium-, and high-dose LHQG groups, the ribavirin tablets group, and the Lianhua Qingwen capsules group showed an increasing trend, but there was no statistical difference.

[0425] Table 31 Effects on lung macrophages and spleen NK cells ( n=6)

[0426]

[0427] Note: Compared with the normal control group + P≤0.05; ++ P≤0.01; compared with the model control group * P≤0.05, ** P≤0.01.

[0428] 4) Effects on pathological changes in lung tissue

[0429] As shown in Table 32 and Figures 7 and 8, Figure 7 shows the results of the pathological effects on lung tissue 24 hours after infection: A, normal control group; B, model control group; C, ribavirin tablet group; D, Lianhua Qingwen capsule group; E, LHQG low-dose group; F, LHQG medium-dose group; G, LHQG high-dose group; black arrows indicate alveoli; blue arrows indicate pulmonary interstitium; red arrows indicate bronchioles, Figure 8 shows the results of the pathological effects on lung tissue 2 hours after the last administration: A, normal control group; B, model control group; C, ribavirin tablet group; D, Lianhua Qingwen capsule group; E, LHQG low-dose group; F, LHQG medium-dose group; G, LHQG high-dose group; black arrows indicate alveoli; blue arrows indicate pulmonary interstitium; red arrows indicate bronchioles.

[0430] Twenty-four hours after exposure, the bronchi and alveoli in the normal control group showed clear structures and neatly arranged cells. In the model control group, significant alveolar wall collapse and rupture, thickening of the bronchiolar walls, partial mucosal cell shedding, and extensive inflammatory cell infiltration were observed, with significantly elevated pathological scores (P ≤ 0.01). The severity of lesions in the medium- and high-dose LHQG, ribavirin tablet, and Lianhua Qingwen capsule groups was significantly less severe than in the model control group, with significantly lower pathological scores (P ≤ 0.05 or P ≤ 0.01). Although lung tissue lesions were alleviated with the low-dose LHQG, no statistically significant differences in pathological scores were observed. Two hours after the last dose, the bronchi and alveoli in the normal control group showed clear structures and neatly arranged cells. In the model control group, partial alveolar wall collapse and rupture, interstitial thickening, bronchial wall thickening, and inflammatory cell infiltration were observed, with significantly elevated pathological scores (P ≤ 0.01). Compared with the model control group, the lesion severity of the medium- and high-dose LHQG groups, the ribavirin tablets group, and the Lianhua Qingwen capsules group was significantly alleviated, and the pathological scores were significantly reduced (P≤0.05 or P≤0.01). Compared with the model control group, although the lung tissue lesions of the low-dose LHQG group were alleviated, there was no statistical difference in the pathological scores.

[0431] Table 32 Effects on lung tissue pathology ( n=10)

[0432]

[0433] Note: Compared with the normal control group ++ P≤0.01; compared with the model control group *P≤0.05, **P≤0.01.

[0434] 5) CD4 + 、CD8 + The influence of lymphocytes

[0435] As shown in Table 33 and Figures 9 and 10, Figure 9 shows the CD4 + 、CD8 + The results of the influence of cell fluorescence intensity value: CD4 + 、CD8 + Signal merge diagram, A, normal control group; B, model control group; C, ribavirin tablets group; D, Lianhua Qingwen capsule group; E, LHQG low-dose group; F, LHQG medium-dose group; G, LHQG high-dose group, Figure 10 is the CD4 + 、CD8 + The results of the influence of cell fluorescence intensity value: CD4 + 、CD8 +Signal merge diagram, A, normal control group; B, model control group; C, ribavirin tablet group; D, Lianhua Qingwen capsule group; E, LHQG low-dose group; F, LHQG medium-dose group; G, LHQG high-dose group.

[0436] 24h after exposure and 2h after the last administration, the number of CD4 + / CD8 + were significantly decreased (P≤0.01), suggesting that RSV infection in mice would cause CD4 + 、CD8 + Compared with the model control, 24 hours after infection, the CD4 + / CD8 + Compared with the model control group, the CD4 + / CD8 + were significantly increased (P≤0.01), indicating that oral administration of LHQG could inhibit the expression of CD4 + 、CD8 + Lymphocyte imbalance.

[0437] Table 33 Pair of lung group CD4 + / CD8 + Effect of immunohistochemical fluorescence intensity ratio ( n=6)

[0438]

[0439] (Note: Compared with the normal control group ++ P≤0.01; compared with the model control group * P≤0.05, ** P≤0.01.

[0440] The above experimental results show that LHQG can reduce the lung index and inhibit the replication of respiratory syncytial virus in the lungs. At the same time, low, medium and high doses of LHQG can reduce the accumulation of inflammatory factors in the lungs and improve the lung pathological changes of infected model mice. LHQG can also increase the number of CD4 + / CD8 +The results showed that LHQG has the function of regulating immune cells and maintaining immune balance, indicating that the Chinese medicine composition of the present invention has a significant anti-respiratory syncytial virus effect in vivo, which may be related to its ability to regulate the balance of immune cells in the body and local lung tissue and inhibit local inflammatory response in the lung tissue.

[0441] Pharmacological studies have confirmed that the traditional Chinese medicine composition LHQG provided by the present invention has the effects of dispelling pathogenic factors, strengthening the body's resistance, overall regulation, treating both the lung and the defense system, and actively intervening.

[0442] Eliminate pathogens and strengthen the body, overall regulation: Studies have shown that LHQG can not only effectively eliminate pathogens, but also mobilize immune functions. In vitro antiviral efficacy studies have shown that LHQG has in vitro antiviral effects on multiple strains of influenza A virus, influenza B virus, respiratory syncytial virus and coronavirus, and acts on the early stages of viral replication. In vivo efficacy studies have further confirmed that LHQG has significant in vivo anti-influenza A virus and anti-respiratory syncytial virus efficacy, and can also increase the number of CD4 in peripheral blood and lung tissue. + / CD8 + Ratio, reducing the M1 / M2 ratio of lung macrophages, enhancing the body's resistance to external viral infections, mobilizing anti-disease immune function, and preventing recurrent upper respiratory tract infections. LHQG is not only effective against cold viruses, but also targets cold-related clinical symptoms, exerting a comprehensive therapeutic effect of antipyretic, analgesic, expectorant, and antitussive effects.

[0443] Lung health and protection: Active intervention: LHQG significantly reduces the expression of host cell inflammatory factors induced by influenza virus and LPS, demonstrating a clear in vitro anti-inflammatory effect. In vivo, it effectively reduced the levels of inflammatory factors (IL-1β, TNF-α, IL-10, and INF-γ) in the lungs of mice infected with respiratory syncytial virus, protected alveolar wall structure, reduced inflammatory cell infiltration, decreased interstitial lung thickness, and improved lung pathological damage. It also effectively inhibited the cold-induced lung inflammatory response, reduced inflammatory factor levels, improved lung pathological damage, treated the cold itself, and prevented progression to pneumonia.

[0444] From the above data, it can be seen that the traditional Chinese medicine composition with the efficacy of treating children's colds provided by the embodiment of the present invention comprises 11 medicinal ingredients, and the monarch, minister, adjuvant and guiding herbs complement each other. The whole formula coordinates the exogenous pathogens with the internal clearing of lung heat, and combines clearing and strengthening the body. It is safe and reliable, and has no toxic side effects. It can not only effectively treat children's colds, but also has the effects of antipyretic, anti-inflammatory, analgesic, cough relieving and expectorant, and can also resist respiratory tract infection viruses, and can be used to prevent and treat viral respiratory tract infections (viral upper respiratory tract infections and viral lower respiratory tract infections), with significant effects.

Claims

1. A Chinese medicine composition for treating colds in children, It is characterized in that The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 250-400 parts of forsythia, 250-400 parts of honeysuckle, 50-150 parts of ephedra, 50-150 parts of bitter almond, 250-400 parts of gypsum, 250-400 parts of isatis root, 50-150 parts of patchouli, 30-90 parts of rhubarb, 10-50 parts of rhodiola, 120-280 parts of mint and 50-150 parts of liquorice.

2. The Chinese medicine composition according to claim 1, It is characterized in that The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 250 parts of forsythia, 400 parts of honeysuckle, 50 parts of ephedra, 150 parts of bitter almonds, 250 parts of gypsum, 400 parts of isatis root, 50 parts of patchouli, 90 parts of rhubarb, 10 parts of rhodiola rosea, 280 parts of mint and 50 parts of liquorice.

3. The Chinese medicine composition according to claim 1, It is characterized in that The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 400 parts of forsythia, 250 parts of honeysuckle, 150 parts of ephedra, 50 parts of bitter almond, 400 parts of gypsum, 250 parts of isatis root, 150 parts of patchouli, 30 parts of rhubarb, 50 parts of rhodiola rosea, 120 parts of mint and 150 parts of liquorice.

4. The Chinese medicine composition according to claim 1, It is characterized in that The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 328 parts of forsythia, 328 parts of honeysuckle, 98 parts of ephedra, 98 parts of bitter almond, 328 parts of gypsum, 328 parts of isatis root, 98 parts of patchouli, 66 parts of rhubarb, 33 parts of rhodiola, 197 parts of mint and 98 parts of liquorice.

5. The Chinese medicine composition according to claim 1, It is characterized in that The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 280 parts of forsythia, 360 parts of honeysuckle, 60 parts of ephedra, 120 parts of bitter almonds, 280 parts of gypsum, 360 parts of isatis root, 60 parts of patchouli, 60 parts of rhubarb, 20 parts of rhodiola, 250 parts of mint and 60 parts of liquorice.

6. The Chinese medicine composition according to any one of claims 1 to 5, It is characterized in that The ephedra is honey ephedra, and the bitter almonds are fried bitter almonds.

7. Use of the Chinese medicine composition according to any one of claims 1 to 5 in the preparation of medicines for treating children's colds, It is characterized in that The cold is influenza or the common cold.

8. The use according to claim 7, It is characterized in that The drug is used in preparing a therapeutic antipyretic drug.

9. The use according to claim 7, It is characterized in that The drug is used in the preparation of anti-inflammatory and analgesic drugs.

10. The use according to claim 7, It is characterized in that The medicine is used in preparing medicines for treating cough, nasal congestion and sore throat.

11. Use of the Chinese medicine composition according to any one of claims 1 to 5 in the preparation of drugs for resisting respiratory tract infection viruses.

12. The use according to claim 11, It is characterized in that The anti-respiratory tract infection virus drug is a drug for treating viral upper respiratory tract infection and / or viral lower respiratory tract infection.

13. The use according to claim 12, It is characterized in that The anti-respiratory tract infection virus medicine is a medicine for treating acute rhinitis, acute pharyngitis, tonsillitis and laryngitis.

14. The use according to claim 11, It is characterized in that The anti-respiratory tract infection virus drug is a drug for treating acute tracheobronchitis or pneumonia.

15. Use of the Chinese medicine composition described in any one of claims 1-5 in resisting H1N1, H3N2, H9N2, H6N2, H7N3, FluB, hRHV, RSV, ADV3, HSV-1, EV71, PR8, AichiH3N2, 09H1, or hCoV-229E virus.

16. Use of the Chinese medicine composition according to any one of claims 1 to 5 in inhibiting MDCK, Hep-2, Huh-7, MRC-5 or Vero cells.

17. Use of the Chinese medicine composition according to any one of claims 1 to 5 in reducing the mRNA level expression of inflammatory factors MIP-1β, IFN-β, IP-10, IL-6, CCL5, MCP-1, TNF-α, RIG-I, MIG or CXCL1.

18. Use of the Chinese medicine composition according to any one of claims 1 to 5 in reducing the expression of influenza virus NP protein.

19. Use of the Chinese medicine composition according to any one of claims 1 to 5 in a drug for inhibiting the increase of lung index and reducing the content of IL-1β, TNF-α, IL-10 or INF-γ in lung tissue.

20. Use of the Chinese medicine composition according to any one of claims 1 to 5 in improving the imbalance of CD4+ and CD8+ lymphocyte ratios in lung tissue, improving the imbalance of M1 and M2 macrophage ratios in lung tissue, and inhibiting the polarization of M1 macrophages.

21. The Chinese medicine composition according to any one of claims 1 to 5, It is characterized in that The active ingredients of the Chinese medicine composition are prepared by the following steps: (1) Weighing patchouli and mint according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain a volatile oil extract for later use; (2) weighing the medicinal ingredients except those in step (1) according to the prescription amount, adding water to boil, combining the filtrate with the volatile oil extract in step (1), concentrating, filtering and setting aside; The volatile oil obtained in step (1) and the extract obtained in step (2) together constitute the active ingredient of the Chinese medicine composition of the present invention.

22. The Chinese medicine composition according to claim 21, It is characterized in that The active ingredients of the Chinese medicine composition are prepared by the following steps: (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water, extract volatile oil by steam distillation for 8 hours, collect the volatile oil and set aside; filter the aqueous solution after distillation to obtain volatile oil extract and set aside; (2) Weigh the amount of the medicinal ingredients except the medicinal ingredients in step (1) according to the prescription, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60° C.), filter, and set aside; The volatile oil obtained in step (1) and the extract obtained in step (2) together constitute the active ingredient of the Chinese medicine composition of the present invention.

23. The Chinese medicine composition according to any one of claims 1 to 5, It is characterized in that The dosage form of the Chinese medicine composition is capsule, tablet, granule, injection, pill, powder and oral liquid.

24. The Chinese medicine composition according to claim 23, It is characterized in that The granules are prepared by the following steps: (1) Weighing patchouli and mint according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain a volatile oil extract for later use; (2) weighing the medicinal ingredients except those in step (1) according to the prescription amount, adding water and boiling, combining the filtrate with the volatile oil extract obtained in step (1), concentrating, filtering, and drying to obtain a dry paste powder for later use; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound; (4) Add appropriate amount of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), and granulate them to prepare granules according to conventional methods.

25. The Chinese medicine composition according to claim 23, It is characterized in that The granules are prepared by the following steps: (1) Weigh patchouli and mint according to the prescribed amount and add 10 times the amount of water, extract volatile oil by steam distillation for 8 hours, collect the volatile oil and set aside; filter the aqueous solution after distillation to obtain volatile oil extract and set aside; (2) Weigh the amount of the medicinal ingredients except the medicinal ingredients in step (1) according to the prescription, add 10 times the amount of water and boil twice, each time for 2 hours, filter, combine the filtrate with the volatile oil extract in step (1), and concentrate under reduced pressure to an extract with a relative density of 1.15±0.05 (60° C.), filter, spray dry to obtain a dry paste powder, and set aside; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound; (4) Add appropriate amount of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), adopt dry granulation method, and prepare granules according to conventional methods.

26. The Chinese medicine composition according to claim 23, It is characterized in that The tablet is prepared by the following steps: (1) Weighing patchouli and mint according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain a volatile oil extract for later use; (2) weighing the medicinal ingredients except those in step (1) according to the prescription amount, adding water and boiling, combining the filtrate with the volatile oil extract obtained in step (1), concentrating, filtering, and drying to obtain a dry paste powder for later use; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound; (4) Add appropriate amount of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3), and prepare tablets according to conventional methods.

27. The Chinese medicine composition according to claim 23, It is characterized in that The capsule is prepared by the following steps: (1) Weighing patchouli and mint according to the prescribed amount, extracting volatile oil by steam distillation, collecting the volatile oil for later use; filtering the aqueous solution after distillation to obtain a volatile oil extract for later use; (2) weighing the medicinal ingredients except those in step (1) according to the prescription amount, adding water and boiling, combining the filtrate with the volatile oil extract obtained in step (1), concentrating, filtering, and drying to obtain a dry paste powder for later use; (3) The volatile oil obtained in step (1) is included with beta-cyclodextrin to obtain a volatile oil inclusion compound; (4) Add appropriate amount of auxiliary materials to the dry paste powder obtained in step (2) and the volatile oil inclusion compound obtained in step (3) and prepare capsules according to conventional methods.